Page 1 Extracted Terms:
**Key heart‑disease related terms**

- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndromes (NST‑ACS)  
- Coronary Artery Disease (CAD)  
- Primary Percutaneous Coronary Intervention (PCI)  
- Dual Antiplatelet Therapy (DAPT)  
- Coronary Artery Revascularization  
- Myocardial Infarction (MI)  
- Coronary Angiography  
- Cardiac Catheterization  
- ACS Management Guideline  
- Revascularization Therapy  
- Cardiovascular Interventions  
- Emergency Cardiovascular Care  
- Cardiovascular Angioplasty  

These terms capture the core concepts and clinical interventions discussed in the guideline text.

Page 2 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Segment Elevation Myocardial Infarction (NSTEMI/NSTE‑ACS)  
- Unstable Angina  
- Coronary Syndromes  
- Fibrinolytic Therapy (Fibrinolytic Agents)  
- Percutaneous Coronary Intervention (PCI)  
- Primary PCI (PPCI)  
- Urgent Coronary Artery Bypass Grafting (CABG)  
- Antiplatelet Therapy  
- Aspirin (acetylsalicylic acid)  
- P2Y12 Inhibitors (oral and intravenous)  
- Glycoprotein IIb/IIIa Inhibitors  
- Parenteral Anticoagulation (heparin, enoxaparin, etc.)  
- Anticoagulants (general)  
- Beta‑Blocker Therapy  
- Renin‑Angiotensin‑Aldosterone System (RAAS) Inhibitors (ACE inhibitors, ARBs, aldosterone antagonists)  
- Lipid Management (statins, LDL‑c reduction)  
- Oxygen Therapy  
- Analgesics (morphine, etc.)  
- Cardiogenic Shock  
- Risk Stratification Tools (e.g., TIMI, GRACE scores)  
- Prehospital Assessment and Management  
- Emergency Medical Services (EMS)  
- Regional STEMI Care Systems  
- Intravenous Glycoprotein IIb/IIIa Inhibition  
- Intravenous P2Y12 Inhibition  
- Use of Aspiration Thrombectomy  
- Use of Intracoronary Imaging (IVUS, OCT)  
- Vascular Access Approach for PCI (radial vs femoral)  
- Routine Invasive vs Selective Invasive Approach in NSTE‑ACS  
- Multivessel Coronary Disease Management in ACS  
- Revascularization Strategies in Cardiogenic Shock  

These terms capture the core heart‑disease concepts and therapeutic approaches outlined in the guideline.

Page 3 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation ACS (STEMI)  
- Non‑ST‑segment elevation ACS (NSTEMI)  
- Cardiogenic Shock  
- Mechanical complications of ACS  
- Electrical complications of ACS  
- Sudden cardiac death  
- Pericarditis after myocardial infarction (MI)  
- Left ventricular (LV) thrombus after MI  
- Cardiac Intensive Care Unit (CICU)  
- Dual Antiplatelet Therapy (DAPT)  
- Aspirin  
- P2Y12 inhibitor  
- Ticagrelor  
- Prasugrel  
- Clopidogrel  
- Triple antiplatelet therapy  
- Proton pump inhibitor (PPI)  
- Bleeding risk management in ACS  
- Long‑term anticoagulation in ACS  
- High‑intensity statin therapy  
- Low‑density lipoprotein (LDL) cholesterol  
- Ezetimibe  
- Evolocumab  
- Alirocumab  
- Inclisiran  
- Bempedoic acid  
- Lipid‑lowering agents  
- SGLT‑2 inhibitors  
- GLP‑1 receptor agonists  
- Chronic colchicine therapy  
- Immunization (vaccine recommendations)  
- Invasive strategy (angiography, revascularization)  
- Percutaneous Coronary Intervention (PCI)  
- Radial access approach (radial artery)  
- Femoral access approach  
- Intracoronary imaging  
- Risk stratification (ischemic risk, bleeding risk)  
- Coronary artery disease (CAD)  
- Revascularization (stenting, CABG)  
- Mechanical circulatory support (MCS)  
- Anemia management in ACS  
- Telemetry monitoring  
- Length of hospital stay  
- Non‑invasive diagnostic testing before discharge  
- Discharge planning  
- Patient education  
- Post‑discharge follow‑up  
- Cardiac rehabilitation  
- Secondary prevention strategies  
- Evidence gaps and future research directions  


Page 4 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted**

- Complete revascularization  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation acute coronary syndrome (NSTE‑ACS)  
- Coronary artery bypass graft (CABG)  
- Multivessel percutaneous coronary intervention (PCI)  
- Cardiogenic shock  
- Microaxial flow pump (intra‑aortic balloon pump, V‑AX, Impella, etc.)  
- Red blood cell transfusion  
- Hemoglobin level (10 g/dL target)  
- Secondary prevention (post‑discharge care)  
- Fasting lipid panel  
- Lipid‑lowering therapy (statins, PCSK9 inhibitors, etc.)  
- Cardiac rehabilitation (in‑person & home‑based programs)  
- Cardiovascular disease (CVD)  
- Cardiovascular health  
- Clinical practice guidelines  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Revascularization strategy  
- Culprit vessel  
- Non‑infarct‑related arteries  
- Bleeding complications  
- Limb ischemia  
- Renal failure  
- Vascular access  
- Weaning of mechanical support  
- Clinical judgment  
- Shared decision‑making  
- Patient engagement  

These terms capture the central concepts, interventions, and policy references relevant to heart disease within the guideline excerpt.

Page 5 Extracted Terms:
Acute coronary syndrome  
Angina, unstable  
Anticoagulants  
Aspirin  
Atrial fibrillation  
Cardiovascular diseases  
Coronary artery disease (CAD)  
Coronary syndrome  
Emergency medical services  
Fibrinolytic agents  
Major adverse cardiovascular events (MACE)  
Morphine  
Myocardial infarction  
Non–ST-elevation myocardial infarction (NSTEMI)  
Percutaneous coronary intervention (PCI)  
Prehospital  
Revascularization  
Risk  
ST-elevation myocardial infarction (STEMI)  
Time factors  
Treatment outcome  
Guideline-directed medical therapy  
Clinical evaluation  
Diagnostic testing  
Pharmacological treatments  
Procedural treatments  
Cardiovascular community  
Heart disease

Page 6 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Primary Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Revascularization  
- Dual Antiplatelet Therapy (DAPT)  
- Coronary Artery Disease (CAD)  
- Acute Myocardial Infarction (AMI)  
- Myocardial Infarction (MI)  
- Recurrent MI  
- Secondary Prevention  
- Guideline‑Recommended Medications  
- Guideline‑Directed Medical Therapy  
- Coronary Revascularization  
- Cardiac Imaging  
- Interventional Cardiology  
- Cardiovascular Surgery  
- Critical‑Care Cardiology  
- Cardiovascular Risk Factors  
- Racial and Sex Disparities in ACS Care  

(Each term is a key concept pertaining to heart disease extracted from the guideline text.)

Page 7 Extracted Terms:
- Acute Coronary Syndromes  
- Acute Myocardial Infarction  
- Coronary Artery Disease  
- Coronary Artery Revascularization  
- Chronic Coronary Disease  
- Myocardial Infarction (non‑obstructive)  
- Invasive Management of Acute Myocardial Infarction  
- Invasive Management of Acute MI Complicated by Cardiogenic Shock  
- Cardiogenic Shock  
- Classification of Cardiogenic Shock  
- SHOCK Stage Classification  
- Mechanical Complications of Acute Myocardial Infarction  
- Diagnosis and Management of Chest Pain  
- Cardiac Catheterization Laboratory Management of Out‑of‑Hospital Cardiac Arrest  
- Management of Heart Failure  
- Atrial Fibrillation Management  
- Left Ventricular Thrombus Management  
- Cardiac Rehabilitation  
- Blood Cholesterol Management  
- Hypertension (High Blood Pressure) Management  
- Stroke Prevention in Stroke and Transient Ischemic Attack  
- Prevention of Cardiovascular Disease  
- Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults  
- Diagnosis and Management of Atrial Fibrillation  
- Management of Patients with Chronic Coronary Disease  
- Invasive Management of Acute MI with Cardiogenic Shock (specific to acute MI)

Page 8 Extracted Terms:
- ACEi – Angiotensin‑converting enzyme inhibitor
- ACS – Acute coronary syndromes
- AF – Atrial fibrillation
- AMI – Acute myocardial infarction
- ARB – Angiotensin receptor blocker
- ASCVD – Atherosclerotic cardiovascular disease
- CABG – Coronary artery bypass grafting
- CAD – Coronary artery disease
- CCD – Chronic coronary disease
- CDP – Clinical decision pathway
- CICU – Cardiac intensive care unit
- CR – Cardiac rehabilitation
- cTn – Cardiac troponin
- CVD – Cardiovascular disease
- DAPT – Dual antiplatelet therapy
- DOAC – Direct oral anticoagulant
- ECG – Electrocardiogram
- FDA – U.S. Food and Drug Administration
- FFR – Fractional flow reserve

Page 9 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Unstable angina  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Myocardial infarction (MI)  
- Myocardial ischemia  
- Coronary artery  
- Plaque rupture  
- Plaque erosion  
- Atherosclerosis  
- Thrombosis  
- Coagulation cascade  
- Myonecrosis  
- First medical contact (FMC)  
- Glucagon‑like peptide‑1 (GLP‑1)  
- Heart failure (HF)  
- High‑sensitivity cardiac troponin (hs‑cTn)  
- Intra‑aortic balloon pump (IABP)  
- Implantable cardioverter‑defibrillator (ICD)  
- Intravascular ultrasound (IVUS)  
- Low‑density lipoprotein (LDL)  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Left ventricle (LV)  
- Left ventricular ejection fraction (LVEF)  
- Major adverse cardiovascular event (MACE)  
- Mechanical circulatory support (MCS)  
- Myocardial infarction with non‑obstructive coronary artery disease (MINOCA)  
- Multivessel disease (MVD)  
- Non‑ST‑segment elevation acute coronary syndrome (NSTE‑ACS)  
- Optical coherence tomography (OCT)  
- Odds ratio (OR)  
- Percutaneous coronary intervention (PCI)  
- Proprotein convertase subtilisin/kexin type 9 (PCSK9)  
- Primary percutaneous coronary intervention (PPCI)  
- Proton pump inhibitor (PPI)  
- Quality of life (QOL)  
- Randomized controlled trial (RCT)  
- Return of spontaneous circulation (ROSC)  
- Sodium‑glucose cotransporter‑2 (SGLT‑2)  
- Unfractionated heparin (UFH)  
- Veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO)  
- Coronary artery spasm  
- Coronary embolism  
- Coronary artery dissection  
- Epicardial vessel  
- Plaque contents exposure  
- Plaque instability  
- Thrombus formation  
- Intrinsic flow compromise in myocardium  
- Atherosclerotic plaque instability  
- Coagulation cascade activation  
- Myocardial necrosis (myonecrosis)

Page 10 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial ischemia  
- Cardiovascular complications  
- Recurrent cardiovascular events  
- Acute inflammatory milieu  
- Stable coronary disease  
- Chronic coronary disease (CCD)  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- 12‑lead ECG  
- STEMI (ST‑segment elevation myocardial infarction)  
- NSTE‑ACS (non‑ST‑segment elevation acute coronary syndrome)  
- Primary percutaneous coronary intervention (PPCI)  
- PCI‑capable hospital  
- Emergency medical services (EMS)  
- First medical contact (FMC)  
- Time to reperfusion  
- Cardiac catheterization team  
- Arrhythmias  
- Cardiac arrest  
- Vital signs  
- Electrocardiographic interpretation for suspected ACS  
- Ischemic changes on ECG  
- ST‑segment depression ≥0.5 mm in ≥2 contiguous leads  
- T‑wave inversion >1 mm in ≥2 contiguous leads  
- ST‑segment elevation ≥1 mm in ≥2 contiguous leads (J‑point)  
- R wave prominence or R/S ratio >1  
- Left ventricular hypertrophy (LVH)  
- Left bundle branch block (LBBB / LBBB)  
- Brugada syndrome  
- Right ventricular pacing  
- Takotsubo syndrome (stress‑cardiomyopathy)  
- Early repolarization pattern  
- Posterior leads (V7–V9)  
- Left circumflex occlusion  
- Acute myocardial infarction (AMI)  
- J‑point definition  
- V2–V3 lead criteria (male/female thresholds)  
- Acute pericarditis  
- STEMI equivalent conditions  
- Prehospital assessment and management of suspected ACS  
- Primary PCI triage strategy  
- STEMI recognition and activation protocol  
- ECG serial monitoring for nondiagnostic STEMI  
- Critical time metrics: FMC‑to‑first‑device ≤90 min  
- Early advance notification to PCI‑capable hospital  
- EMS transport for suspected ACS  
- Structured prehospital history and physical examination  
- Hemodynamic monitoring during transport  
- Early reperfusion strategy  
- Emergency department (ED) triage for ACS  
- Clinical suspicion of ACS  
- Persistent chest pain symptoms  
- Dynamic ST‑segment changes  
- Coronary artery disease (CAD)  
- Coronary artery occlusion  
- Cardiac catheterization procedure  
- Reperfusion therapy  
- Cardiovascular event prevention  
- Post‑acute management of ACS  
- Medication therapy for stable coronary disease  
- Extended therapy beyond one year post‑ACS  
- Acute coronary event classification (STEMI vs. NSTE‑ACS)  
- ECG interpretation criteria (ST‑depression, ST‑elevation, T‑wave changes)  
- ECG lead placement for posterior ischemia  
- Age‑ and sex‑based ST‑elevation thresholds  
- Cardiac ischemia diagnosis and management guidelines  

*(List includes core clinical, diagnostic, therapeutic, and guideline‑related terms pertinent to heart disease found in the provided text.)

Page 11 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- ST‑segment elevation (STEMI criteria)  
- 12‑lead electrocardiogram (ECG)  
- Electrocardiographic tracings  
- Coronary reperfusion  
- Percutaneous coronary intervention (PCI)  
- Primary PCI (PPCI)  
- PCI‑capable facility  
- Cardiogenic shock  
- Heart failure (HF)  
- Ventricular arrhythmias  
- Prehospital setting  
- Emergency medical services (EMS) personnel (paramedics)  
- Cardiac complications  
- Triage to PCI‑capable facility  



Page 12 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation ACS (NSTE‑ACS)  
- Electrocardiogram (ECG)  
- ST‑segment elevation  
- Posterior STEMI  
- Pre‑hospital ECG  
- Primary percutaneous coronary intervention (PPCI or PPCI)  
- Coronary reperfusion  
- First‑medical‑contact (FMC)  
- PCI‑capable hospital  
- Catheterization laboratory activation  
- Single‑call transfer protocol  
- ED bypass to catheterization laboratory  
- Acute myocardial infarction (AMI)  
- Type 1 myocardial infarction (Type 1 MI)  
- Type 2 myocardial infarction (Type 2 MI)  
- Type 3 myocardial infarction (Type 3 MI)  
- Type 4a peri‑PCI myocardial infarction (PCI MI)  
- Type 4b post‑PCI myocardial infarction (stent‑related MI)  
- Type 4c post‑PCI myocardial infarction (stent restenosis)  
- Type 5 peri‑coronary artery bypass grafting myocardial infarction (CABG MI)  
- Myocardial infarction with non‑obstructive coronary arteries (MINOCA)  
- Spontaneous coronary artery dissection (SCAD)  
- Infarct‑related artery  
- Reperfusion time  
- Time‑to‑device  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)

Page 13 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non–ST‑segment Elevation ACS (NSTE‑ACS)  
- Myocardial Infarction (MI)  
- Acute Myocardial Infarction (AMI)  
- Cardiac Troponin (cTn)  
- High‑Sensitivity Cardiac Troponin (hs‑cTn)  
- 12‑lead Electrocardiogram (ECG)  
- Serial ECG monitoring  
- Chest pain  
- Cardiogenic shock  
- Hemodynamic instability  
- Mechanical complications (of the heart)  
- Cardiac catheterization  
- Fibrinolytic therapy  
- Reperfusion therapy  
- Posterior STEMI  
- Right ventricular involvement  
- Major Adverse Cardiovascular Events (MACE)

Page 14 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Cardiac troponin (cTn)  
- High‑sensitivity cardiac troponin (hs‑cTn)  
- Clinical decision pathway (CDP)  
- Risk categories: low, intermediate, high risk  
- Class of Recommendation  
- Chest pain  
- AHA/ACC/Multisociety guideline  
- 2025 Acute Coronary Syndromes Guideline  
- 2021 Chest Pain Guideline

Page 15 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment–elevation myocardial infarction (STEMI)  
- Non–ST‑segment–elevation myocardial infarction (NSTEMI)  
- Unstable angina  
- Acute coronary event  
- Myocardial ischemia  
- Cardiac injury  
- High‑sensitivity cardiac troponin (hs‑cTn)  
- Cardiac troponin (cTn) assay  
- 99th percentile upper reference limit  
- Delta hs‑cTn (change in troponin)  
- Cardiac Diagnostic Pathway (CDP)  
- Serial troponin testing (0, 1–2 h)  
- ST‑segment deviation  
- Killip class (II–IV)  
- Pulmonary congestion (clinical, CXR, lung US)  
- Heart failure (HF)  
- Major Adverse Cardiac Events (MACE)  
- Myocardial infarction (MI)  
- Coronary artery disease (CAD)  
- Coronary stenosis (≥50 %)  
- Creatine kinase‑myocardial band (CK‑MB)  
- B‑type natriuretic peptide (BNP)  
- N‑terminal pro‑BNP (NT‑proBNP)  
- International guidelines (e.g., Circulation ACS guideline)  
- Global Registry of Acute Coronary Events (GRACE) risk score  
- Thrombolysis In Myocardial Infarction (TIMI) risk score  
- Aspirin use (pre‑hospital/within 7 days)  
- Time to treatment (>4 h)  
- Invasive vs. selective invasive strategy (routine invasive approach)  
- Left bundle branch block (LBBB)  
- High‑negative predictive value (>99.5 %)  
- Diagnostic thresholds for hs‑cTn  
- Cardiovascular event risk assessment  
- Revascularization (urgent/refractory)  

These terms capture the key heart‑disease concepts discussed in the text.

Page 16 Extracted Terms:
**Key terms related to heart disease**

- Acute Coronary Syndromes (ACS)  
- Acute Myocardial Infarction (AMI)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑STEMI (NSTEMI)  
- B‑type Natriuretic Peptide (BNP)  
- Cardiogenic Shock  
- Cardiac Arrest  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Angiography  
- Mechanical Circulatory Support (MCS)  
  - (Sub‑types: Intra‑Aortic Balloon Pump, Impella, ECMO – commonly referenced in MCS)  
- Shock Severity Scales (risk‑stratification tools for cardiogenic shock)  
- Major Adverse Cardiac Events (MACE)  
- Heart Failure (HF)  
- Electrocardiogram (ECG) / Electrocardiographic changes (ST‑segment elevation)  
- Return of Spontaneous Circulation (ROSC)  
- Shockable Rhythm (ventricular fibrillation, ventricular tachycardia)  
- Non‑shockable Rhythm (asystole, pulseless electrical activity)  
- Advanced Reperfusion Strategies (e.g., ARREST trial, CARES registry)  

These terms encapsulate the central concepts, diagnostic markers, management strategies, and outcome metrics discussed in the guideline excerpts.

Page 17 Extracted Terms:
**Key heart‑disease‑related terms extracted from the guideline text**

- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation ACS (NSTE‑ACS)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Emergency coronary angiography  
- Delayed coronary angiography  
- Cardiac arrest (post‑CPR, comatose)  
- Hemodynamic stability  
- Neurologic recovery / prognosis  
- Hypoxia (oxygen saturation < 90 %)  
- Supplemental oxygen therapy  
- Oxygen saturation (SpO₂)  
- Angina / chest pain  
- Myocardial oxygen supply  
- Vasoconstriction  
- Oxidative stress  
- Myocardial injury  
- Infarct size  
- Short‑term mortality  
- Long‑term mortality  
- Re‑hospitalization with MI  
- U‑shaped oxygenation–mortality relationship  
- AVOID (Air Versus Oxygen in STEMI) trial  
- DETO2X‑AMI (Efficacy and Outcome Study of Supplemental Oxygen Treatment in MI) trial  
- Analgesic therapies in ACS  
- Nitrates  
- Opiate medications  
- Routine vs. conservative oxygen administration  
- Clinical benefit (or lack thereof)  
- Cardiovascular outcomes  

These terms capture the core clinical concepts, interventions, outcomes, and study references addressed in the guideline excerpt.

Page 18 Extracted Terms:
**Key heart‑disease terms extracted from the guidelines**

- Acute Coronary Syndromes (ACS)  
- Angina / Anginal pain  
- Antiplatelet therapy  
- Antiplatelet therapy in patients on anticoagulation post‑discharge  
- Aspirin  
- Aspirin desensitization (for hypersensitivity)  
- Aspirin hypersensitivity  
- Aspirin loading dose (162–325 mg)  
- Aspirin maintenance dose (75–100 mg/day)  
- Aspirin discontinuation strategy  
- Atherothrombotic events  
- Baseline management strategy (invasive or non‑invasive)  
- Bleeding risk (minor and gastrointestinal bleeding)  
- Calcium channel blockers (mentioned in context of anti‑ischemic therapy)  
- Coronary artery disease (CAD)  
- Coronary events (MI, stroke)  
- Dual Antiplatelet Therapy (DAPT)  
- Dual antiplatelet therapy in ACS  
- Dual antiplatelet therapy discontinuation (P2Y12 inhibitor discontinuation)  
- Dual antiplatelet therapy in the first 12 months post‑discharge  
- Dual antiplatelet therapy during hospitalization (oral P2Y12 inhibitors)  
- Drug interactions with opiates and oral P2Y12 inhibitors  
- End points: mortality, MACE (major adverse cardiovascular events)  
- Gastric / intestinal absorption of P2Y12 inhibitors  
- Glycoprotein IIb/IIIa inhibitors (in the broader guideline context)  
- Myocardial infarction (MI)  
- Non‑aspirin non‑steroidal anti‑inflammatory drugs (NSAIDs) – their impact on MACE risk  
- Oral P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel, etc.)  
- PCI (Percutaneous Coronary Intervention)  
- Post‑discharge antiplatelet therapy  
- Right ventricular infarction (RV infarction)  
- Stroke (as a cardiovascular event)  
- Titrated intravenous (IV) nitrates (e.g., nitroglycerin)  
- Vascular death  
- Vascular events (including MI and stroke)  
- Vascular death after AMI  
- Non‑invasive management of ACS  
- Invasive strategy for ACS (including PCI)  
- Pharmacodynamics of oral antiplatelet therapy  
- Pharmacologic delay of P2Y12 inhibitor effects by opioids (morphine, fentanyl)  

*These terms capture the clinical concepts, therapies, and outcomes discussed in the extracted guideline text that are directly relevant to heart disease management.*

Page 19 Extracted Terms:
Acute Coronary Syndromes (ACS)  
ST‑segment elevation myocardial infarction (STEMI)  
Non–ST‑segment elevation acute coronary syndromes (NSTE‑ACS)  
Atherosclerotic cardiovascular disease (ASCVD)  
Myocardial infarction (MI)  
Major adverse cardiovascular events (MACE)  
Platelet‑activating factor P2Y12 receptor inhibitors  
Clopidogrel  
Prasugrel  
Ticagrelor  
Aspirin (low‑dose, 81 mg, 75‑100 mg)  
High‑dose aspirin (162‑325 mg)  
Loading dose (aspirin, clopidogrel, prasugrel, ticagrelor)  
Maintenance dose (aspirin, clopidogrel, prasugrel, ticagrelor)  
Percutaneous coronary intervention (PCI)  
Primary percutaneous coronary intervention (PPCI)  
Fibrinolytic therapy  
Stent thrombosis  
Platelet aggregation  
Bleeding risk (major bleeding, increased risk of bleeding)  
Net clinical outcomes (stroke, transient ischemic attack)  
Antiplatelet therapy (dual antiplatelet therapy, DAPT)  
Coronary artery revascularization  
Chronic coronary disease guidelines  
Guideline recommendations  
Evidence grade (COR, LOE)

Page 20 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑segment Elevation ACS (NSTE‑ACS)  
- Myocardial Infarction (MI)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Dual Antiplatelet Therapy (DAPT)  
- Coronary Artery Disease (CAD)  
- Coronary Thrombosis / Stent Thrombosis  
- Major Adverse Cardiac Events (MACE)  
- Bleeding Risk / Bleeding Complications  
- Net Clinical Benefit (MACE + Bleeding)  
- Oral P2Y12 Inhibitors  
- Clopidogrel  
- Prasugrel  
- Ticagrelor  
- Aspirin (ASA)  
- Platelet Activation / Inhibition  
- Transient Dyspnea  
- Pharmacodynamic Variability  
- Hyporesponder Status  
- Fibrinolytic Therapy  
- Transient Ischemic Attack (TIA)  
- Stroke  
- Body Weight Threshold (<60 kg)  
- Age Threshold (≥75 years)  
- Platelet Inhibition Loading Dose  
- Metabolic Transformation (liver biotransformation)  
- Drug Potency (clopidogrel vs prasugrel vs ticagrelor)  
- DAPT Strategy Guidelines (Section 11.1)  
- Clinical Trial: TRITON‑TIMI 38  
- Clinical Trial: PLATO  
- Clinical Trial: TRITON‑TIMI 38, PLATO, and other RCTs mentioned  
- Net Harm (prasugrel vs clopidogrel in certain subgroups)  
- DAPT Duration after CABG  
- DAPT Duration in the first 12 months post‑discharge  
- Platelet Inhibition Variability in Clopidogrel  
- Risk of Bleeding in P2Y12 Inhibitor Therapy  
- Primary Prevention of STEMI/PCR  
- Secondary Prevention after ACS  

These terms capture the diseases, treatments, risk factors, clinical outcomes, and guideline recommendations discussed in the provided text.

Page 21 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Non‑ST‑Elevation ACS (NSTE‑ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Myocardial Infarction (MI)  
- Cardiovascular death  
- Stroke  
- Stent thrombosis  
- Percutaneous Coronary Intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Invasive strategy  
- Elective CABG  
- Urgent CABG  
- Major Adverse Cardiac Events (MACE)  
- Ischemic events  
- Bleeding (including non‑CABG major bleeding and life‑threatening bleeds)  
- Clopidogrel (P2Y12 inhibitor, prodrug)  
- Prasugrel (P2Y12 inhibitor)  
- Ticagrelor (P2Y12 inhibitor)  
- P2Y12 inhibitor therapy  
- Vascular death  
- Coronary anatomy  
- Coronary angiography  
- Pretreatment (loading dose)  
- Cytochrome P450 enzyme system (metabolism of clopidogrel)  
- CURE trial (Clopidogrel in Unstable Angina to Prevent Recurrent Events)  
- PLATO trial (P2Y12 inhibitor study of ticagrelor vs. clopidogrel)  
- TRITON‑TIMI 38 trial (pragmatic comparison of prasugrel and clopidogrel)  
- Open‑label trial (comparative efficacy of prasugrel vs. ticagrelor)  
- Meta‑analysis of clopidogrel in ACS undergoing PCI  

Page 22 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑STEMI Acute Coronary Syndromes (NSTE‑ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Primary PCI (PPCI)  
- Coronary Reperfusion / Revascularization  
- Stent Thrombosis  
- Major Adverse Cardiac Events (MACE)  
- Cardiovascular Death  
- Myocardial Infarction (MI)  
- Stroke  
- Bleeding (minor & major)  
- Antiplatelet Therapy  
- P2Y12 Inhibitors  
- Clopidogrel  
- Prasugrel  
- Ticagrelor  
- Cangrelor (intravenous P2Y12 antagonist)  
- Fibrinolytic Therapy  
- CABG (Coronary Artery Bypass Grafting)  
- Loading Dose (300 mg then 75 mg daily)  
- Intravenous vs Oral P2Y12 inhibition  
- Preloading / Pre‑administration of P2Y12 inhibitors  
- Pre‑hospital ticagrelor  
- TRITON‑TIMI 38 trial  
- PLATO trial  
- CLARITY‑TIMI 28 trial  
- COMMIT trial  
- Intravenous cangrelor trials (RCTs 1–3)  
- Meta‑analysis on clopidogrel pretreatment  
- Registry data on preloading efficacy  
- Transition strategy from intravenous to oral P2Y12 inhibition  
- Clinical endpoints: death, reinfarction, stroke, ischemic events, bleeding.

Page 23 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Segment Elevation Acute Coronary Syndrome (NSTE‑ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Revascularization  
- Cangrelor  
- Clopidogrel  
- Prasugrel  
- Ticagrelor  
- P‑2Y12 inhibitors  
- Glycoprotein IIb/IIIa inhibitors  
- Abciximab  
- Eptifibatide  
- Tirofiban  
- Glycoprotein IIb/IIIa receptor  
- Intravenous glycoprotein IIb/IIIa inhibitors  
- Intracoronary glycoprotein IIb/IIIa inhibitors  
- Large thrombus burden  
- No‑reflow  
- Slow flow  
- Stent thrombosis  
- Intraprocedural ischemic events  
- Infarct size  
- Drug‑eluting stents  
- Coronary thrombus resolution  
- Peri‑procedural ischemic events  
- Ischemia‑driven revascularization  
- Bleeding risk (in context of glycoprotein inhibitors)  
- Intravenous bolus  
- Intravenous infusion  
- Loading dose  
- Adjunctive therapy  
- Rescue or bail‑out therapy  
- Upstream administration  
- Clinical guideline recommendations (e.g., 2025 ACS Guideline, 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization)

Page 24 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Non–ST‑Segment Elevation ACS (NSTE‑ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Angiography  
- Glycoprotein IIb/IIIa Inhibitor  
- Eptifibatide  
- Clopidogrel  
- Bleeding Complications  
- Ischemic Events  
- Parenteral Anticoagulation  
- Unfractionated Heparin (UFH)  
- Enoxaparin  
- Fondaparinux  
- Bivalirudin  
- Fibrinolytic Therapy  
- Catheter Thrombosis  
- Major Adverse Cardiac Events (MACE)  
- Atherothrombosis  
- Thrombin Generation  
- Platelet Aggregation  
- Heparin‑Induced Thrombocytopenia (HIT)  
- Argatroban  
- Low‑Molecular‑Weight Heparin (LMWH)  
- Coronary Artery Revascularization  
- Coronary Plaque Rupture  
- Plaque Erosion  
- Type‑1 Myocardial Infarction (MI)  
- Stress Cardiomyopathy  
- Myocarditis  
- EARLY‑ACS Trial (Early Glycoprotein IIb/IIIa Inhibition in Non‑ST‑Elevation ACS)

Page 25 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Non‑ST‑elevation Acute Coronary Syndromes (NSTE‑ACS)  
- ST‑elevation Myocardial Infarction (STEMI)  
- Myocardial Infarction (MI)  
- Unstable Angina  
- Coronary Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Dual Antiplatelet Therapy (DAPT)  
- Aspirin  
- Heparin (unfractionated heparin, UFH)  
- Heparin‑induced Thrombocytopenia (HIT)  
- Low‑molecular‑weight Heparin (LMWH) – e.g., enoxaparin  
- Fondaparinux  
- Bivalirudin  
- Antithrombin  
- Factor Xa  
- Thrombin  
- Activated Clotting Time (ACT)  
- Activated Partial Thromboplastin Time (aPTT)  
- Catheter Thrombosis  
- Ischemic Events  
- Major Bleeding  
- Bleeding Academic Research Consortium (BARC)  
- Creatinine Clearance (CrCl) (relevant to drug dosing in cardiovascular therapy)

Page 26 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndrome (NSTE‑ACS)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Percutaneous Coronary Intervention (PCI)  
- Unfractionated Heparin (UFH)  
- Low‑molecular‑weight heparin (Enoxaparin)  
- Bivalirudin  
- Fondaparinux  
- Glycoprotein IIb/IIIa inhibitors  
- Stent thrombosis  
- Major bleeding  
- Major Adverse Cardiovascular Events (MACE)  
- Ischemic outcomes  
- Mortality / Death  
- Recurrent acute coronary syndromes (ACS)  
- Urgent revascularization  
- Catheter thrombosis  
- Coronary complications  
- Fibrinolytic therapy  
- Thrombolytic agents (streptokinase, tissue plasminogen activator)  
- Heparin infusion  
- Subcutaneous enoxaparin injections  
- ExTRACT‑TIMI 25 trial  
- GUSTO trial  
- ASSENT‑3 trial  
- ACUITY trial  
- MATRIX trial  
- OASIS‑5 trial  
- OASIS‑6 trial  
- Meta‑analysis of ACS trials

Page 27 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI)  
- Major Adverse Cardiovascular Events (MACE)  
- Low‑Density Lipoprotein Cholesterol (LDL‑C)  
- High‑intensity statin therapy  
- Moderate‑intensity statin therapy  
- Statin intolerance  
- Non‑statin lipid‑lowering therapy  
- Ezetimibe  
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors  
- Monoclonal antibodies to PCSK9  
- Bempedoic acid  
- Inclisiran  
- Coronary Artery Disease (CAD)  
- Cardiovascular death  
- Ischemic stroke  
- ASCVD (Atherosclerotic Cardiovascular Disease) event rates  
- LDL‑cholesterol target levels  
- Lipid profile measurement  
- Lipid management post‑ACS  
- Cholesterol Treatment Trialists (CTT) meta‑analysis  
- A to Z (Aggrastat to Zocor) study  
- PROVE IT‑TIMI 22 trial  
- IMPROVE IT trial  

Page 28 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Non‑ST‑Elevation Myocardial Infarction (NSTEMI)  
- Acute Myocardial Infarction (AMI)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Cardiovascular Disease (CVD)  
- Low‑Density Lipoprotein Cholesterol (LDL‑C)  
- Major Adverse Cardiovascular Events (MACE)  
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)  
- Niemann‑Pick C1‑Like 1 protein (NPC1L1)  
- Evolocumab (PCSK9 monoclonal antibody)  
- Alirocumab (PCSK9 monoclonal antibody)  
- Inclisiran (small interfering RNA PCSK9 inhibitor)  
- Bempedoic Acid (ATP‑citrate lyase inhibitor)  
- Ezetimibe (NPC1L1 cholesterol‑absorption inhibitor)  
- Statin therapy (high‑dose; statin‑related adverse effects)  
- Intracoronary imaging (plaque assessment & regression)  
- Plaque regression / plaque components  
- Injection‑site reaction (adverse effect of PCSK9 therapies)  
- Elevated liver‑function tests (adverse effect of ezetimibe)  
- Gout and gallstones (adverse effect of bempedoic acid)  
- Muscle‑related adverse effects (increased with concomitant statins)  
- FDA approval status (regulatory context for cardiovascular drugs)

Page 29 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Acute Coronary Syndromes  
- Statin intolerance  
- Statin-associated muscle symptoms  
- Ezetimibe  
- PCSK9 inhibitors (monoclonal antibodies)  
- Inclisiran  
- Bempedoic acid (ATP citrate lyase inhibitor)  
- Bempedoic acid + ezetimibe combination therapy  
- Major Adverse Cardiovascular Events (MACE)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Hyperlipidemia  
- High‑intensity statin therapy  
- Moderate‑intensity statin therapy  
- Low‑intensity statin therapy  
- Atorvastatin (40‑80 mg)  
- Rosuvastatin (20‑40 mg)  
- Atorvastatin (10‑20 mg)  
- Rosuvastatin (5‑10 mg)  
- Simvastatin (20‑40 mg; 10 mg)  
- Pravastatin (40‑80 mg; 10‑20 mg)  
- Lovastatin (40 mg; 20 mg)  
- Fluvastatin XL (80 mg)  
- Fluvastatin (40 mg BID; 20‑40 mg)  
- Pitavastatin (1‑4 mg)  
- IMPROVE IT trial  
- FOURIER trial  
- ODYSSEY OUTCOMES trial  
- CLEAR Outcomes trial  
- Neurocognitive events  
- Hemorrhagic stroke  
- Polyvascular disease  
- Coronary disease  
- Diabetes mellitus (as a cardiovascular risk factor)  
- Elevated cardiovascular biomarkers  
- Secondary cardiovascular prevention  
- Cardiovascular outcomes research  
- Niemann‑Pick C1‑Like 1 protein (NPC1L1)  
- Statin‑intolerant patient management strategies  
- LDL‑C lowering efficacy (≥50 %, 30‑49 %, <30 %)

Page 30 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Segment Elevation Acute Coronary Syndrome / NSTEMI (NSTE‑ACS)  
- Early initiation of oral beta‑blocker therapy  
- Beta‑blockers (e.g., metoprolol, carvedilol)  
- Myocardial oxygen demand reduction (via heart rate, blood pressure, contractility)  
- Left ventricular ejection fraction (LVEF) < 40 %  
- Stabilized heart failure (HF)  
- Post‑myocardial infarction (post‑MI) patients  
- Pre‑reperfusion era trials  
- Killip class II‑IV acute heart failure  
- Low cardiac output state / cardiogenic shock risk  
- PR interval > 0.24 ms  
- Second‑ or third‑degree heart block (without pacemaker)  
- Severe bradycardia  
- Active bronchospasm  
- Randomized controlled trials (RCTs)  
- COMMIT trial (Clopidogrel and Metoprolol in Myocardial Infarction)  
- Metoprolol high‑dose IV/PO therapy  
- Intravenous beta‑blocker use prior to reperfusion  
- Carvedilol in STEMI with PCI  
- Major adverse cardiovascular events (MACE)  
- Renin‑Angiotensin‑Aldosterone System (RAAS) inhibitors  
- Angiotensin‑converting enzyme inhibitor (ACE‑i)  
- Angiotensin receptor blocker (ARB)  
- Mineralocorticoid receptor antagonist  
- All‑cause death  
- High‑risk ACS (LVEF ≤ 40 %, hypertension, diabetes mellitus, anterior STEMI)  
- Coronary revascularization (PCI/CABG)  
- Clinical benefit of long‑term beta‑blocker therapy post‑discharge  
- Optimal beta‑blocker duration in preserved LVEF patients.

Page 31 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Acute Coronary Syndromes  
- Acute Myocardial Infarction (AMI)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Heart Failure (HF)  
- Left Ventricular Systolic Dysfunction  
- Left Ventricular Ejection Fraction (LVEF)  
- Angiotensin‑Converting Enzyme Inhibitor (ACEi)  
- Angiotensin Receptor Blocker (ARB)  
- Mineralocorticoid Receptor Antagonist  
- Eplerenone  
- Sacubitril‑Valsartan  
- Major Adverse Cardiovascular Events (MACE)  
- All‑cause death  
- Cardiovascular death  
- Hypotensive events  
- Hyperkalemia  
- Chronic kidney disease  
- Survival benefit  
- Natriuretic peptides  
- Beta blocker  
- Percutaneous Coronary Intervention (PCI)  
- Reperfusion therapy  
- Regional STEMI care  
- Prehospital STEMI care  
- Hospital‑based STEMI care  
- Total ischemic time  
- Cardiac surgical care  
- Advanced care modalities  
- 30‑day mortality  
- Non‑fatal cardiac failure  

These terms capture the principal diagnoses, therapeutic agents, clinical outcomes, and care‐system concepts discussed in the guideline excerpt.

Page 32 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Reperfusion  
- First Medical Contact (FMC)  
- Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Cardiac Catheterization Laboratory  
- Emergency Medical Services (EMS)  
- Emergency Department (ED)  
- Electrocardiogram (ECG)  
- Ischemic Symptoms  
- Heart Attack  
- STEMI Performance Measures  
- Class of Recommendation  
- Cardiac Catheterization Center  
- FMC‑to‑Device Time  
- STEMI Care System Pathway  



Page 33 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Emergency Medical Services (EMS)  
- Primary Percutaneous Coronary Intervention (PPCI / PPCI)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Cardiogenic shock  
- Hemodynamic instability  
- Infarct‑related artery  
- Myocardial salvage  
- First medical contact (FMC) to device activation time  
- Ischemic symptoms  
- Ongoing ischemia  
- Life‑threatening arrhythmia  
- Fibrinolytic therapy  
- TIMI 3 epicardial flow grade  
- Radial vascular access  
- Femoral vascular access  
- Intracranial hemorrhage  
- Acute kidney injury  
- Recurrent ischemia  
- Reinfarction  
- Emergency revascularization  
- SHOCK trial (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock)  
- AHA Mission: Lifeline program  
- STEMI care system (regional STEMI system of care)  
- Emergency revascularization strategy  
- Early death reduction  
- Clinical outcomes (survival, infarct size, reperfusion success)  
- Data collection and sharing in STEMI care  
- Transfer time to PCI‑capable hospital  
- AHA/AACC/SCAI Guidelines for Coronary Artery Revascularization  
- Coronary artery disease (implied context)

Page 34 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Primary Percutaneous Coronary Intervention (PPCI) / PCI  
- Coronary Artery Bypass Grafting (CABG)  
- Cardio‑gic Shock  
- Left Ventricular Ejection Fraction (LVEF)  
- Major Adverse Cardiac Events (MACE)  
- Myocardial Infarction (MI)  
- Fibrinolytic Therapy  
- First Medical Contact (FMC)  
- Reperfusion Strategy  
- Non‑PCI‑Capable Hospital  
- Intravenous Thrombolysis  
- In‑hospital Mortality  
- Ongoing Ischemia  
- Infarct Size  
- Multivessel Coronary Artery Disease (CAD)  
- Mechanical Complications (e.g., mechanical valve failure, ventricular rupture)  
- Outcomes: Mortality at 30 days, 6 months, 1 year, 6 years  
- Clinical Trials / Studies:  
  - FITT‑STEMI trial  
  - Occluded Artery Trial (OAT)  
  - DECOPI (Desobstruction Coronaire en Post‑Infarctus)  
  - 2025 Acute Coronary Syndromes Guideline  
  - 2021 ACC/AHA/SCAI Guideline for Coronary Artery Re‑vascularization  
- Guidelines:  
  - "Revascularization in ACS With Cardiogenic Shock"  
  - "Mechanical Complications"  
  - "Management of Multivessel CAD in STEMI"

Page 35 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non‑STEMI (implied as other ACS presentations)  
- Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Fibrinolytic therapy  
- Myocardial Infarction (MI)  
- Coronary reperfusion  
- Reperfusion modality  
- Major Adverse Cardiac Events (MACE)  
- Hemodynamic instability  
- Infarct size  
- Large infarct territory  
- Hemorrhagic stroke  
- Major noncerebral bleeding  
- Congestive heart failure (CHF)  
- Shock  
- Reinfarction  
- Late presenters (12‑24 hours after symptom onset)  
- Pre‑hospital fibrinolysis  
- Pharmaco‑invasive approach (fibrinolysis followed by PCI)  
- TIMI (not explicitly mentioned, but related to reperfusion)  
- STREAM trial (Strategic Reperfusion Early After Myocardial Infarction)  
- Time to first medical contact (FMC)  
- Time from FMC to device activation (≤120 minutes threshold)  
- Time from symptom onset (≤12 hours window)  
- Time‑dependent reduction in mortality and morbidity  
- Tenecteplase  
- Alteplase  
- Reteplase  
- Fibrin‑specific fibrinolytic agents  
- Non‑fibrin‑specific agents  
- Patency rates  
- Immunogenicity  
- Recurrent MACE  
- Non‑PCI‑capable hospital  
- PCI‑capable hospital  
- Reperfusion strategy  
- Recurrent morbidity and mortality rates  
- Early presenters (≤3 hours after symptom onset)  
- Large anterior infarction  
- Low bleeding risk  
- Large area of myocardium at risk  
- Revascularization  
- Coronary artery disease (implied)  
- Reperfusion delay  
- Transfer delays  
- Reperfusion benefit  
- Clinical benefit  
- Morbidity and mortality rates  
- Recurrent myocardial infarction  
- Recurrent cardiac events  

(Note: Each entry represents a key term or concept related to heart disease and its management as extracted from the guideline text.)

Page 36 Extracted Terms:
- Acute Coronary Syndromes  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Myocardial Infarction (MI)  
- Fibrinolytic Therapy  
- Alteplase (tPA)  
- Tenecteplase (TNK‑tPA)  
- Reteplase (rPA)  
- Coronary Angiography  
- Percutaneous Coronary Intervention (PCI)  
- Rescue PCI  
- Reperfusion  
- Failed Reperfusion  
- Re‑occlusion  
- Coronary Revascularization  
- Intracranial Hemorrhage (as a contraindication to fibrinolysis)  
- ST‑segment Elevation (definition criteria)  
- Hemodynamic Instability  
- Electrical Instability  
- Ischemic Stroke (relevant contraindication)  
- Antiplatelet Therapy  
- Anticoagulant Therapy  
- Catheterization  
- Transfer to PCI‑capable Center  
- Parenteral Anticoagulation  
- Oral P2Y12 Inhibitors  
- Fibrin‑Specific Fibrinolytic Agents  
- ST‑segment Elevation Resolution Criteria  
- Cardiogenic Shock (implied by hemodynamic instability)  
- Aortic Dissection (contraindication but relevant to cardiac care)

Page 37 Extracted Terms:
- Acute coronary syndromes (ACS)  
- Non‑ST‑segment elevation acute coronary syndrome (NSTE‑ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Coronary angiography  
- Percutaneous coronary intervention (PCI)  
- Fibrinolytic therapy (fibrinolysis)  
- Reperfusion  
- Recurrent ischemic events  
- Major adverse cardiovascular events (MACE)  
- Myocardial infarction (MI) / reinfarction  
- Heart failure (HF)  
- Early invasive strategy  
- Routine invasive strategy  
- Selective invasive strategy  
- Pharmaco‑invasive strategy  
- Revascularization  
- Hemodynamic instability  
- Electrical instability  
- Refractory angina  
- Early transfer to specialized center  
- Femoral artery access  
- Radial artery access  
- Glycoprotein IIb/IIIa inhibitors  
- Antiplatelet therapy  
- Anticoagulant therapy  
- Blowing (major/minor) bleeding  
- Stroke  
- Death  
- Intermediate, high, and low risk of ischemic events  
- Clinical trials, meta‑analyses, network meta‑analysis (study designs)  
- Composite primary endpoints (death, reinfarction, stroke, HF)  
- Timing of angiography (≤24 hours, >24 hours, immediate)  
- Recurrent coronary artery stenosis or suboptimal flow  
- Treatment arms (rescue PCI, conservative care, repeat fibrinolytic therapy)  
- Era of reperfusion therapy (fibrinolysis‑only, pharmaco‑invasive, PPCI)  
- Outcomes: mortality, reduced MACE, bleeding rates, rehospitalisation.

Page 38 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Non‑ST‑segment Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- Recurrent MI  
- Recurrent Ischemia  
- Major Adverse Cardiovascular Events (MACE)  
- Coronary Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Coronary Angiography  
- Invasive Approach (Routine Invasive Strategy)  
- Selective Invasive Approach  
- Non‑invasive Risk Stratification  
- Non‑invasive Stress Testing  
- Coronary CT Angiography (CCTA)  
- Cardiac Computed Tomography (CT) Angiography  
- Cardiac Biomarkers  
- High‑Sensitivity Cardiac Troponin (hs‑cTn)  
- Hematology‑Guided Antiplatelet Therapies  
- Drug‑Eluting Stents (DES)  
- Radial Approach for Coronary Angiography  
- Acute Coronary Syndrome Guidelines  
- Myocardial Infarction with Non‑Obstructive Coronary Artery Disease (MINOCA)  
- Non‑obstructive Coronary Artery Disease  
- AHA Scientific Statement  
- Hospital Discharge in ACS management  
- Recurrent Ischemic Symptoms  
- Non‑invasive Testing Prior to Discharge  
- Invasive Coronary Angiography Prior to Discharge  
- Class of Recommendation (for guideline tiers)

Page 39 Extracted Terms:
Acute Coronary Syndromes (ACS)  
Non‑ST‑Elevation Acute Coronary Syndromes (NSTE‑ACS)  
NSTEMI (Non‑ST‑Elevation Myocardial Infarction)  
Unstable Angina  
Coronary Angiography  
Routine Invasive Strategy  
Selective Invasive Approach  
Revascularization  
Percutaneous Coronary Intervention (PCI)  
Coronary Artery Bypass Grafting (CABG)  
Myocardial Infarction (MI)  
Major Adverse Cardiovascular Events (MACE)  
GRACE Risk Score  
TIMI Risk Score  
Cardiac Biomarkers  
CK‑MB (Creatine Kinase MB)  
Troponin (conventional, older generation)  
High‑Sensitivity Cardiac Troponin (hs‑cTn)  
Coronary CT Angiography  
Noninvasive Stress Testing  
Refractory or Recurrent Angina  
Hemodynamic Instability  
Electrical Instability  
Acute Pulmonary Edema  
Heart Failure (HF)  
Mitral Regurgitation  
PCI‑Capable Hospital  
Dual Antiplatelet Therapy (DAPT)  
Bleeding Risk  
Thrombocytopenia (platelet count <50 × 10⁹/L)  
Advanced Kidney Disease (non‑dialysis)  
Acute Renal Failure  
Limited Life Expectancy (<1‑2 years)  
Advanced Dementia  
Coronary Anatomy precluding PCI/CABG  
Patient Preference  
Emergency Invasive Strategy (<2 hours from admission)  
Timing of Intervention (Early vs Delayed)  
TIMACS Trial (Timing of Intervention in Acute Coronary Syndromes)  
VERDICT Trial (Very Early vs Deferred Invasive Evaluation)  
GRACE Risk Score >140  
Diabetes  
Age >75 years  
Steep Rise in Cardiac Biomarkers (ongoing ischemia)

Page 40 Extracted Terms:
**Key terms related to heart disease (from the excerpt provided):**

1. Acute Coronary Syndromes (ACS)  
2. Non–ST‑segment elevation acute coronary syndromes (NSTE‑ACS)  
3. Percutaneous Coronary Intervention (PCI)  
4. Transradial access / radial approach  
5. Transfemoral access / femoral approach  
6. Radial artery  
7. Femoral artery  
8. Coronary artery bypass graft (CABG)  
9. Bypass conduit (radial artery, ulnar artery, distal radial artery)  
10. Mechanical circulatory support (MCS)  
11. Ultrasound guidance (for vascular access)  
12. Bleeding complications  
13. Vascular complications  
14. Mortality / death  
15. Hemorrhage / bleeding risk  
16. Global Registry of Acute Coronary Events (GRACE) score  
17. Heart failure (HF)  
18. Troponin (Tn)  
19. Thrombolysis in Myocardial Infarction (TIMI)  
20. Ventricular fibrillation (VF)  
21. Ventricular tachycardia (VT)  
22. ACC/AHA/SCAI Guideline  
23. Cardiovascular Surgical Team  
24. Heart Team approach  
25. CATHETERIZATION LABORATORY recommendations  
26. Evidence Table / Level of Evidence (LOE)  
27. Class of Recommendation (COR)  
28. Meta‑analysis (individual patient data)  
29. Clinical, anatomical, or technical reasons (affecting access choice)  

These terms capture the key concepts and entities related to the management and complications of heart disease discussed in the text.

Page 41 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Percutaneous Coronary Intervention (PCI)  
- Transradial approach  
- Transfemoral approach  
- Radial access  
- Femoral access  
- Major bleeding  
- Vascular complications  
- MACE (Major Adverse Cardiovascular Events)  
- Net adverse clinical events  
- Coronary artery revascularization  
- Aspiration thrombectomy  
- Myocardial infarction (MI) size  
- Left ventricular (LV) function  
- Coronary patency  
- Coronary thrombus  
- Balloon angioplasty  
- Stent deployment  
- Stent malapposition  
- Coronary dissections  
- Intravascular ultrasound (IVUS)  
- Optical coherence tomography (OCT)  
- Coronary stent implantation  
- Left main artery lesions  
- Complex lesions  
- Recurrent myocardial infarction  
- Target vessel revascularization  
- Stent thrombosis  
- Heart failure (HF)  
- Stroke / transient ischemic attack  
- Thrombus burden  
- No‑reflow phenomenon

Page 42 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Acute Coronary Syndromes (ACS)  
- Coronary artery disease (CAD)  
- Multivessel coronary artery disease (MVD)  
- ST‑segment–elevation myocardial infarction (STEMI)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Left main coronary artery disease  
- Target vessel failure  
- Cardiac death  
- Target vessel myocardial infarction (MI)  
- Ischemia‑driven target vessel revascularization  
- Target lesion revascularization  
- Stent thrombosis (definite or probable)  
- Major adverse cardiac events (MACE)  
- Minimum stent area (MSA)  
- Malapposition  
- Underexpansion  
- Tissue protrusion  
- Edge disease / edge dissection  
- Optical coherence tomography (OCT)  
- Intravascular ultrasound (IVUS)  
- Intracoronary imaging guidance  
- Angiographic guidance  
- Intracoronary imaging (general)  
- Calcification extent  
- Lipid presence  
- Thrombus formation  
- Fibroatheroma  
- Plaque rupture  
- Plaque burden  
- Plaque length  
- External elastic lamina diameter  
- Coronary artery diameter stenosis severity  
- Cardiogenic shock  
- Renal failure (associated risk in PCI)

These terms represent the core concepts, diagnostic features, interventions, and outcomes discussed in the provided guideline excerpt.

Page 43 Extracted Terms:
**Key terms related to heart disease extracted from the guideline text:**

- Acute Coronary Syndromes (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Major adverse cardiovascular events (MACE)  
- Myocardial infarction (MI)  
- Recurrent MI  
- Recurrent ischemia  
- Cardiac mortality (cardiovascular death)  
- Angina (refractory angina)  
- Angina‑related quality of life (QOL)  
- Coronary artery disease (CAD)  
- Multivessel coronary artery disease (MVD)  
- Complete revascularization (CR)  
- Culprit artery only revascularization  
- Staged percutaneous coronary intervention (PCI)  
- Immediate (single‑procedure) multivessel PCI  
- Physiology‑guided PCI  
- Fractional flow reserve (FFR)  
- Angiography‑guided PCI  
- Coronary artery bypass grafting (CABG)  
- Left main coronary artery disease  
- Left anterior descending (LAD) artery disease  
- Chronic total occlusion (CTO)  
- Diabetes mellitus (as a CAD risk factor)  
- Bleeding risk from dual antiplatelet therapy (DAPT)  
- Ischemia‑driven revascularization  
- Unplanned revascularization  
- Cerebrovascular events  
- Heart failure (HF)  
- Re‑infarction (reinfarction)  
- Hospitalization for heart failure  
- Network meta‑analysis

These terms capture the core concepts, interventions, clinical outcomes, and patient subgroups addressed in the 2025 Acute Coronary Syndromes Guideline.

Page 44 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑segment Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Cardiogenic shock  
- Multivessel Percutaneous Coronary Intervention (PCI)  
- Culprit lesion PCI / culprit‑only PCI  
- Non‑culprit lesion PCI  
- Complete revascularization  
- Staged multivessel PCI  
- Coronary Artery Disease (CAD)  
- Multivessel Disease (MVD)  
- Left Main Coronary Artery stenosis  
- Left Anterior Descending (LAD) artery disease  
- Complex CAD (including left‑main, 3‑vessel, diffuse disease)  
- Diabetes mellitus with coronary involvement  
- Left Ventricular (LV) dysfunction / severe LV dysfunction  
- Major Adverse Cardiovascular Events (MACE)  
- Coronary Artery Bypass Grafting (CABG)  
- Coronary Artery Bypass Grafting (CABG) vs PCI decision  
- Heart Team approach  
- Physiological assessment (e.g., fractional flow reserve) of non‑culprit stenosis  
- Renal replacement therapy / kidney failure in PCI context  
- CULPRIT‑SHOCK trial  
- Right/Left coronary artery involvement  
- Coronary artery bypass grafting (CABG) surgery  
- Percutaneous Coronary Intervention (PCI)  
- Angiographic assessment  
- Clinical outcomes (death, renal outcomes, rehospitalization)  

These terms capture the key heart‑disease concepts and procedures discussed in the guideline excerpt.

Page 45 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non–ST‑segment Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Coronary Artery Bypass Grafting (CABG)  
- Percutaneous Coronary Intervention (PCI)  
- Multivessel Disease (MVD)  
- Major Adverse Cardiac Events (MACE)  
- Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE trial)  
- Single Staged Versus Multistaged PCI in Multivessel NSTEMI Patients (SMILE trial)  
- BIOVASC trial  
- Fractional Flow Reserve (FFR)  
- Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME trial)  
- Fractional Flow Reserve vs. Angiography‑Guided Strategy for Management of Non‑Infarction Related Artery Stenosis in Patients with Acute Myocardial Infarction (FRAME‑AMI trial)  
- Fractional Flow Reserve Versus Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes (FAMOUS‑NSTEMI trial)  
- Cardiogenic Shock  
- CULPRIT‑SHOCK trial  
- Culprit Lesion Only PCI vs. Multivessel PCI  
- Angiography‑guided PCI  
- Culprit‑only PCI  
- Emergency revascularization  
- Hemodynamic instability  
- Renal replacement therapy  
- Survival benefit with revascularization  
- Risk of death or renal failure with multivessel PCI  
- Stent deployment  
- Revascularization procedures  
- Coronary artery revascularization (clinical guideline context)  
- Angiographic assessment of stenosis (≥50 %)  
- Minimum vessel diameter (>2.5 mm)  
- Drug‑eluting stents (implicit in PCI)

Page 46 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial infarction (MI)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Cardiogenic shock  
- Revascularization  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Multivessel PCI  
- Culprit lesion  
- Non‑culprit lesion  
- Microaxial intravascular flow pump (microaxial pump)  
- Intra‑aortic balloon pump (IABP)  
- Venoarterial extracorporeal membrane oxygenation (VA‑ECMO)  
- Mechanical circulatory support (MCS)  
- Hemodynamic stabilization  
- Bridge to surgery  
- Shock (SHOCK) trial  
- CULPRIT‑SHOCK trial  
- FITT‑STEMI trial  
- Primary percutaneous coronary intervention (PPCI)  
- Renal replacement therapy (as outcome endpoint)

Page 47 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Acute Myocardial Infarction (AMI)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Cardiogenic shock  
- DanGer‑SHOCK trial  
- SCAI shock stages (C, D, E)  
- Microaxial flow pump (MCP)  
- Mechanical circulatory support (MCS) devices  
- Intra‑aortic balloon pump (IABP)  
- Veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO)  
- Extracorporeal Life Support (ECLS)  
- ECMO‑CS trial  
- ECLS‑SHOCK trial  
- IABP‑SHOCK II trial  
- Ventricular septal rupture (VSR)  
- Mechanical complications of AMI  
- Bridge to surgery  
- Early revascularization  
- Percutaneous coronary intervention (PCI)  
- End‑organ hypoperfusion  
- Arterial lactate (≥2.5 mmol/L)  
- Central venous oxygen saturation (SvO₂ < 55 %)  
- PaO₂ (oxygen partial pressure)  
- LVEF (left ventricular ejection fraction) < 45 %  
- Hypotension (SBP < 100 mm Hg)  
- Renal replacement therapy  
- Limb ischemia  
- Major bleeding  
- Peripheral vascular complications  
- In‑hospital mortality  
- 30‑day mortality  
- All‑cause mortality  
- Absolute risk reduction  
- Hazard ratio (HR)  
- Odds ratio (OR)  
- Glasgow Coma Scale score < 8  
- Right ventricular failure  
- Overt right ventricular failure  
- Large‑bore access  
- Clinical guidelines (2025 Acute Coronary Syndromes Guideline)

Page 48 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI / AMI)  
- Cardiogenic Shock  
- Mechanical Complications of ACS  
- Ventricular Septal Rupture  
- Mitral Valve Insufficiency (due to papillary muscle infarction)  
- Free Wall Rupture  
- Heart Failure (HF)  
- Sudden Cardiac Death  
- Intra‑Aortic Balloon Pump (IABP)  
- Veno‑Arterial Extracorporeal Membrane Oxygenation (VA‑ECMO)  
- Extracorporeal Life Support (ECLS)  
- Mechanical Circulatory Support (MCS)  
- Temporary MCS Devices  
- Reperfusion Therapy  
- Cardiac Surgical Expertise  
- Cardiac Intensive Care Unit (CICU)  
- Shock Teams  
- Cardiac Transplantation  
- Durable Left Ventricular Assist Device (LVAD)  
- Percutaneous Structural Intervention  
- Acute Mitral Regurgitation  
- Heart Team Approach  
- Early Corrective Surgery  
- Delayed Surgery (post‑AMI)  
- End‑Organ Injury  
- Hemodynamic Stabilization  
- Left‑to‑Right Shunting  
- Multidisciplinary Care  
- Peri‑operative Mortality  

These terms capture the key concepts related to heart disease and its management discussed in the guideline excerpt.

Page 49 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial infarction (MI)  
- Left ventricular ejection fraction (LVEF)  
- Implantable cardioverter‑defibrillator (ICD)  
- Ventricular arrhythmias  
- Sudden cardiac death (SCD)  
- Atrial fibrillation (AF)  
- Atrial flutter  
- Second‑degree atrioventricular block, Mobitz type II  
- High‑grade atrioventricular block  
- Alternating bundle‑branch block  
- Third‑degree atrioventricular block (infranodal)  
- Permanent pacing  
- Temporary wearable cardioverter‑defibrillator  
- Arrhythmic complications  
- Heart failure (HF)  
- Coronary revascularization  
- Percutaneous coronary intervention (PCI)  
- Fibrinolytic therapy  
- Antiarrhythmic therapy  
- Electrophysiologic interventions  
- Mechanical complications of acute myocardial infarction (e.g., rupture, pseudo‑aneurysm)  
- Left atrium (LA)  
- Left ventricle (LV)  
- Mitral regurgitation (MR)  
- National/American Heart Association (AHA), American College of Cardiology (ACC), Heart Rhythm Society (HRS) guideline documents  
- MADIT II (Multicenter Automatic Defibrillator Implantation Trial)  
- Evidence‑based guideline terminology (e.g., “recommended”, “reasonable”)

Page 50 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Prophylactic implantable cardioverter‑defibrillator (ICD) implantation  
- Left Ventricular Ejection Fraction (LVEF)  
- New York Heart Association (NYHA) functional class  
- Ventricular tachycardia (VT)  
- Ventricular fibrillation (VF)  
- Myocardial infarction (MI)  
- Coronary Artery Bypass Grafting (CABG)  
- Sudden cardiac death  
- Beta‑blocker therapy  
- Antiarrhythmic drug therapy  
- Radiofrequency catheter ablation  
- Wearable cardioverter‑defibrillator (WCD)  
- ST‑elevation myocardial infarction (STEMI)  
- High‑degree atrioventricular (AV) block  
- Cardiogenic shock  
- Pericarditis after myocardial infarction  
- Inducible ventricular arrhythmia  
- Temporary pacemaker insertion  
- Permanent pacemaker insertion  
- Defibrillator in Acute Myocardial Infarction Trial (DINAMIT)  
- VEST trial (Vest Prevention of Early Sudden Death)  
- Ventricular arrhythmias occurring >48 hours post‑reperfusion  
- Non‑arrhythmic deaths following ICD implantation or MI  
- LVEF thresholds (≤ 35 % and ≤ 40 %) predictive of ICD benefit

Page 51 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI)  
- Dressler’s syndrome  
- Pericarditis (acute & late)  
- Pericardial effusion  
- High‑dose aspirin therapy  
- Colchicine therapy  
- Glucocorticoids  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Left ventricular (LV) thrombus  
- ST‑segment elevation myocardial infarction (STEMI)  
- Anterior STEMI  
- Left ventricular ejection fraction (LVEF)  
- LV aneurysm  
- Left anterior descending (LAD) artery  
- Echocardiogram (transthoracic echo)  
- Cardiac magnetic resonance imaging (MRI)  
- Dual antiplatelet therapy (DAPT)  
- Anticoagulation (warfarin, DOAC, vitamin K antagonists)  
- Direct oral anticoagulants (DOACs)  
- Vitamin K antagonist  
- Cardiac intensive care unit (CICU)  
- Cardiogenic shock  
- Arrhythmias (torsades, VT/VF)  
- Reperfusion therapy (PCI, thrombolysis)  
- Angina (ongoing)  
- Hemodynamic instability  
- Stroke (thromboembolic complication)  
- Systemic embolization  
- Bleeding risk  
- Thromboembolic risk  
- ECG findings (PR‑segment depression, concave ST elevation, dynamic T‑wave changes)  
- Friction pericardial rub  
- Pleuritic chest pain  
- Residual thrombus monitoring  
- Anticoagulant duration (3 months, prolonged)  
- Imaging for LV thrombus detection  
- Clinical risk assessment for anticoagulation  
- Pericarditis diagnostic criteria  
- Clinical management of pericarditis (aspirin dose, colchicine dosing)

Page 52 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Acute Coronary Syndromes (ACS)  
- Myocardial infarction (MI)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST elevation myocardial infarction (NSTEMI)  
- Cardiac intensive care unit (CICU)  
- Hemodynamic instability  
- Uncontrolled arrhythmias  
- Heart failure (HF)  
- Cardiogenic shock  
- Angina  
- Ischemic symptoms  
- Cardiac catheterization  
- Telemetry monitoring  
- Intermediate care unit  
- ACTION ICU risk score  
- Signs / symptoms of heart failure  
- Heart rate  
- Systolic blood pressure (SBP)  
- Troponin  
- Serum creatinine  
- Prior revascularization  
- Chronic lung disease  
- ST‑segment depression  
- Age > 70 years  
- Anemia  
- Blood transfusion  
- Hemoglobin level (≥ 10 g/dL, < 7–8 g/dL)  
- Cardiovascular events  
- Restrictive transfusion strategy  
- Liberal transfusion strategy  
- Myocardial Ischemia and Transfusion (MINT) trial  
- End‑stage renal disease (ESRD)  
- Cardiac surgery  
- Percutaneous coronary intervention (PCI)  
- Cardiac death  
- Recurrent myocardial infarction  

These terms capture the clinical concepts, procedures, scoring systems, and outcomes discussed in the guideline excerpt.

Page 53 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Segment Elevation Acute Coronary Syndrome (NSTE‑ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Left Ventricular Ejection Fraction (LVEF)  
- Left Ventricular (LV) function  
- Left Ventricular dysfunction  
- Left Ventricular thrombus  
- Ventricular wall motion abnormalities  
- Mechanical complications of MI (e.g., LV free‑wall rupture, papillary muscle rupture)  
- Valvular dysfunction (e.g., mitral regurgitation)  
- Killip class  
- TIMI Flow Grade  
- Zwolle score  
- Troponin (troponin‑negative)  
- Acute kidney injury (AKI)  
- Heart failure (HF)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Telemetry monitoring  
- Continuous ST‑segment monitoring  
- Transthoracic echocardiography (TTE)  
- Cardiac magnetic resonance imaging (CMR)  
- Left ventriculography  
- Myocardial perfusion imaging  
- Revascularization (e.g., coronary revascularization)  
- Clinical risk stratification  
- Early discharge strategy  
- Same‑day discharge  
- Post‑discharge prescription medications  
- Follow‑up after discharge  
- Intermediate care unit (ICU)  

(Note: Terms are listed in bullet format for clarity.)

Page 54 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Coronary heart disease (CHD)  
- Myocardial infarction (MI, sometimes referred to as AMI)  
- Cardiac rehabilitation (CR) – center‑based and home‑based  
- Secondary prevention of cardiovascular disease (CVD)  
- Functional status  
- Quality of life (QOL)  
- Readmission (30‑day readmission)  
- Hospital discharge planning  
- Transition from hospital to home  
- Hospital‑to‑Home Initiative  
- AMI Toolkit  
- Digital health interventions (for transition of care)  
- Risk factor modification (e.g., smoking cessation, physical activity, healthy diet)  
- Medication adherence and optimization  
- Health and nutrition education  
- Psychological support (depression & anxiety screening)  
- Life’s Essential 8 (AHA lifestyle recommendations)  
- Cardiovascular mortality  
- All‑cause death  
- All‑cause hospitalization  
- Under‑utilization of cardiac rehabilitation  
- Intensive care unit (ICU) services (as a readmission risk factor)  
- Chronic coronary disease  
- American Heart Association (AHA) recommendations  
- Cardiovascular disease (CVD)  
- Coronary artery disease (sometimes used interchangeably with CHD)  
- Cardiovascular risk factors (hyperlipidemia, hypertension, diabetes, etc.)  
- Patient education (symptom monitoring, return to daily routine, psychosocial considerations)  
- Multicomponent integrated care (combination of quality improvement strategies)  

These terms capture the principal clinical concepts, interventions, and outcomes discussed in the guideline text regarding heart disease.

Page 55 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial infarction (MI / AMI)  
- Coronary heart disease (CHD)  
- Cardiac rehabilitation (CR)  
- Exercise‑based CR programs  
- Home‑based CR programs  
- Center‑based CR programs  
- Hybrid CR models  
- Digital health tools  
- Remote monitoring  
- Risk factor education and counseling  
- Lifestyle management (dietary counseling, smoking cessation, weight control)  
- Risk factor control (lipids, blood pressure, diabetes)  
- Psychological interventions  
- Re‑infarction risk reduction  
- Cardiovascular mortality  
- Cardiovascular death  
- Recurrent myocardial infarction  
- Rehospitalization  
- Quality of life (QOL)  
- Ischemic symptoms assessment  
- Bleeding risk assessment (medication or procedural)  
- Diagnostic testing (repeat echocardiogram, staged PCI)  
- Influenza vaccination status  
- Medication reconciliation  
- Sublingual nitroglycerin prescribing  
- Primary prevention (secondary prevention)  
- Self‑care education and adherence  
- Social determinants of health (medication access, CR attendance barriers)  

These terms capture the key concepts related to heart disease discussed in the guideline text.

Page 56 Extracted Terms:
- Acute Coronary Syndromes  
- Dual Antiplatelet Therapy (DAPT)  
- Aspirin  
- P2Y12 inhibitor  
- Ticagrelor  
- Clopidogrel  
- Prasugrel  
- Monotherapy  
- Gastrointestinal bleeding  
- Proton Pump Inhibitor (PPI)  
- Percutaneous Coronary Intervention (PCI)  
- Cardiac Rehabilitation  
- Major Adverse Cardiovascular Events (MACE)  
- Oral Anticoagulants  
- Bleeding risk  
- High bleeding risk  
- High gastrointestinal bleeding risk  
- De‑escalation of DAPT  

Page 57 Extracted Terms:
- Acute coronary syndrome (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation acute coronary syndrome (NSTE‑ACS)  
- Unstable angina  
- Dual antiplatelet therapy (DAPT)  
- Aspirin  
- Oral P2Y12 inhibitor  
- Ticagrelor  
- Prasugrel  
- Clopidogrel  
- Ticagrelor monotherapy  
- Clopidogrel monotherapy  
- Aspirin monotherapy  
- De‑escalation strategy (switching P2Y12 inhibitors)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Major adverse cardiovascular events (MACE)  
- Bleeding risk  
- Thrombotic risk  
- Gastrointestinal bleeding  
- Proton pump inhibitor (PPI)  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Platelet inhibition / pharmacodynamic response  
- High bleeding risk  
- High thrombotic risk  
- Early thrombotic events  
- Late thrombotic events  
- Ischemic events / ischemic efficacy  
- Net clinical benefit / harm  
- Shorter DAPT strategy  
- Prothrombotic state  
- CURE trial (Clopidogrel in Unstable Angina to Prevent Recurrent Events)

Page 58 Extracted Terms:
**Key heart‑disease–related terms identified in the text**

- Acute coronary syndromes (ACS)  
- Dual antiplatelet therapy (DAPT)  
- Single antiplatelet therapy (SAPT)  
- Oral anticoagulant (OAC)  
- Percutaneous coronary intervention (PCI)  
- Drug‑eluting stent (DES)  
- Bioresorbable polymer‑coated stent  
- Clopidogrel  
- Ticagrelor  
- Prasugrel  
- P2Y12 inhibitor  
- Platelet function assays  
- Genotyping (CYP2C19 polymorphisms)  
- Proton‑pump inhibitor (PPI) therapy  
- Omeprazole  
- Gastric/ gastrointestinal bleeding  
- Ischemic events (myocardial infarction, stroke)  
- High bleeding risk  
- Guided de‑escalation of DAPT  
- Unguided de‑escalation of DAPT  
- De‑escalation strategy (switching to clopidogrel)  
- Antiplatelet efficacy  
- Bleeding risk reduction  
- Management of high bleeding risk patients (MASTER DAPT trial)  

These terms capture the core concepts related to cardiovascular disease management, antiplatelet therapy, procedural interventions, and associated risks discussed in the excerpt.

Page 59 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Myocardial infarction (MI)  
- Dual antiplatelet therapy (DAPT)  
- Triple antithrombotic therapy  
- Aspirin  
- P2Y12 inhibitors (e.g., clopidogrel, ticagrelor)  
- Clopidogrel  
- Ticagrelor  
- Oral anticoagulant (OAC)  
- Direct oral anticoagulant (DOAC)  
- Vitamin K antagonist (e.g., warfarin)  
- Percutaneous coronary intervention (PCI)  
- High bleeding risk  
- Major bleeding  
- Minor bleeding  
- Major adverse cardiovascular events (MACE)  
- Ischemic events  
- Chronic kidney disease (CKD)  
- Estimated glomerular filtration rate (eGFR)  
- Hemoglobin level  
- Platelet count (thrombocytopenia)  
- Intracranial hemorrhage (ICH)  
- Nonsteroidal anti‑inflammatory drugs (NSAIDs)  
- Steroids  
- Active malignancy  
- Brain arteriovenous malformation  
- Ischemic stroke  
- Anticoagulation therapy  
- Aspirin discontinuation (1–4 weeks post‑ACS)  
- Antiplatelet therapy guidelines  
- Academic Research Consortium (ARC) high‑bleeding‑risk criteria  
- Age ≥ 75 years  
- Long‑term oral anticoagulation  
- Renal function (CKD stages)  
- Major/minor bleeding criteria  
- Non‑deferrable major surgery on DAPT  
- Recent major surgery or trauma (within 30 days)

Page 60 Extracted Terms:
**Key heart‑disease–related terms extracted from the text**

- Acute Coronary Syndromes (ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Dual Antiplatelet Therapy (DAPT)  
- Aspirin  
- P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor)  
- Oral anticoagulant  
- Low‑intensity vs. high‑intensity anticoagulation  
- Atrial fibrillation (AF)  
- Stent thrombosis  
- Myocardial infarction (MI)  
- Coronary revascularization  
- Lipid‑lowering therapy  
- Statin intolerance (requiring ≥2 statins)  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- LDL‑C target levels  
- Major Adverse Cardiovascular Events (MACE)  
- Cardiovascular events (stroke, death, MI, stent thrombosis)  
- High‑potency (high‑intensity) statin  
- LDL‑C lowering strategy (rapid, intensive)  
- Lipid management guidelines  
- Early follow‑up and lipid testing  
- PALM (Provider Assessment of Lipid Management) registry  
- AUGUSTUS trial (antithrombotic therapy after ACS/PCI in AF)  

These terms capture the principal clinical concepts, therapies, outcomes, and guideline recommendations relevant to heart disease discussed in the passage.

Page 61 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial infarction (MI)  
- Heart failure (HF)  
- Left ventricular (LV) systolic function  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary artery disease (CAD)  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular death  
- Resuscitated cardiac arrest  
- Stroke (ischemic)  
- Urgent coronary revascularization  
- Angina  
- Coronary revascularization procedures  
- Coronary artery bypass graft (CABG)  
- Lipid‑lowering therapy  
- Aspirin therapy  
- Statin therapy  
- Glucagon‑like peptide‑1 (GLP‑1) receptor agonists  
- Sodium‑glucose co‑transporter‑2 (SGLT‑2) inhibitors  
- Empagliflozin  
- Dapagliflozin  
- Canagliflozin  
- Ertugliflozin  
- Colchicine  
- Anti‑inflammatory therapy  
- High‑sensitivity C‑reactive protein (hs‑CRP)  
- Plaque volume  
- Non‑cardiovascular death  
- Acute kidney injury  
- Hypovolemia  
- Urinary tract infection  
- Genital mycotic infection  
- Ketoacidosis (perioperative)

Page 62 Extracted Terms:
**Heart‑Disease–Related Terms**

- Acute Coronary Syndrome (ACS)  
- Myocardial infarction (MI)  
- Coronary artery disease / coronary heart disease  
- ST‑segment elevation (ST‑elevation)  
- ST‑segment–elevation myocardial infarction (STEMI)  
- Cardiac arrest  
- Revascularization (e.g., percutaneous coronary intervention – PCI)  
- Primary PCI  
- Fibrinolysis / fibrinolytic therapy  
- Coronary angiography / coronary catheterization  
- Invasive risk stratification  
- Telemetry monitoring  
- Life‑threatening arrhythmias  
- Atrioventricular (AV) block  
- Atrial fibrillation (AF)  
- Ischemia / severe recurrent ischemia  
- Rehospitalization for ischemia  
- Reperfusion therapy  
- Stent thrombosis  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular death  
- Non‑fatal MI  
- Immunization for cardiovascular risk reduction (e.g., influenza vaccine, pneumococcal vaccine)  
- FLUVACS (Flu Vaccination in Acute Coronary Syndromes) study  
- Cardiovascular morbidity and mortality  
- ASCVD (atherosclerotic cardiovascular disease)  
- Risk scores for death/recurrent MI prediction  
- Telemetry duration in ACS management  
- Preloading of oral P2Y12 inhibitors (loading dose prior to angiography)  
- Pulmonary complications (COVID‑19, pneumococcal pneumonia) as cardiovascular event risk enhancers  
- Colchicine use post‑MI (ongoing trials)  

These terms capture the core clinical concepts, interventions, outcomes, and risk factors discussed in the guideline excerpt.

Page 63 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation ACS (NSTE‑ACS)  
- Non‑ST‑Elevation Myocardial Infarction (NSTEMI)  
- Multivessel Disease (MVD)  
- Percutaneous Coronary Intervention (PCI)  
- Culprit‑Only PCI  
- Multivessel PCI  
- Coronary Artery Bypass Graft (CABG)  
- Coronary Angiography  
- Cardiogenic Shock  
- Mechanical Circulatory Support (MCS)  
- Microaxial Flow Pump  
- Chronic Coronary Syndrome (CCS)  
- Left Ventricular Thrombus  
- Antiplatelet Therapy  
- Clopidogrel  
- P2Y12 Inhibitors (oral & parenteral)  
- Beta Blockers  
- Sacubitril‑Valsartan  
- Non‑statin Lipid‑Lowering Therapies  
- PCSK9 Inhibitors  
- GLP‑1 Receptor Agonists  
- Aspirin  
- Direct Oral Anticoagulants (DOACs)  
- Colchicine  
- Post‑MI Pericarditis  
- Cardiac Rehabilitation (CR) – home‐based vs facility‐based  
- Residual Unrevascularized Coronary Artery Disease (CAD)  
- Vascular Complications  
- Bleeding Risk  
- Major Adverse Cardiac Events (MACE)  
- Long‑Term Secondary Prevention  
- Diabetes  
- Overweight/Obesity

Page 64 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Acute Coronary Syndromes (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation acute coronary syndromes  
- Primary percutaneous coronary intervention (PCI)  
- Coronary artery revascularization  
- Coronary artery disease (CAD)  
- Dual antiplatelet therapy (DAPT)  
- Cardiovascular disease  
- Heart disease  
- 2013 ACCF/AHA guideline for the management of ST‑elevation myocardial infarction  
- 2014 AHA/ACC guideline for the management of patients with non‑ST‑elevation acute coronary syndromes  
- 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy  
- 2021 ACC/AHA/SCAI guideline for coronary artery revascularization  
- ACC/AHA clinical practice guidelines  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- SCAI (Society for Cardiovascular Angiography and Interventions)  
- Myocardial infarction  
- Coronary artery disease management  
- Cardiovascular disease and comorbid conditions  
- Heart disease and stroke statistics (circulation data)

Page 65 Extracted Terms:
Acute Coronary Syndromes (ACS)  
Myocardial infarction (MI)  
ST‑segment–elevation myocardial infarction (STEMI)  
Non‑ST‑segment–elevation ACS (NSTE‑ACS)  
Acute coronary syndrome  
Coronary artery disease (CAD)  
Coronary heart disease  
Percutaneous coronary intervention (PCI)  
Coronary stent  
Cardiogenic shock  
Left ventricular thrombus  
Chronic coronary disease  
Atrial fibrillation (AF)  
Heart failure (HF)  
Heart failure with reduced ejection fraction (HFrEF)  
Heart failure with preserved ejection fraction (HFpEF)  
Cardiac rehabilitation  
Chest pain evaluation  
Mechanical complications of MI (e.g., ventricular septal defect, free‑wall rupture)  
Catheterization laboratory management for cardiac arrest  
Out‑of‑hospital cardiac arrest  
Stroke prevention  
Transient ischemic attack (TIA)  
Hypertension  
Elevated blood pressure  
Dyslipidemia / high‑cholesterol / lipid management  
Statins (including high‑intensity statin therapy)  
Low‑density lipoprotein cholesterol (LDL‑C) goals  
Cardiovascular risk factors (e.g., diabetes, smoking)  
Sex, gender, and ethnicity disparities in cardiovascular care  
Racial and ethnic differences in heart disease outcomes  
Sex differences in symptom presentation and treatment of MI  
Pre‑vention and control of hypertension  
Management of patients with left ventricular thrombus  
Guidelines for blood cholesterol management (ACC/AHA)  
Guidelines for prevention, detection, and management of high blood pressure (ACC/AHA)  
Guidelines for primary prevention of cardiovascular disease (ACC/AHA)  
Guidelines for evaluation and diagnosis of chest pain (ACC/AHA)  
Guidelines for prevention of stroke in patients with stroke/TIA (ACC/AHA)  
Guidelines for management of heart failure (ACC/AHA/HFSA)  
Guidelines for management of chronic coronary disease (ACC/AHA)  
Guidelines for diagnosis and management of atrial fibrillation (ACC/AHA)  
Guidelines for home‑based cardiac rehabilitation (ACC/AHA)  
Consensus statements on cardiogenic shock classification (SCAI)  
Consensus updates on cardiogenic shock stages (SCAI)  
Safety and effectiveness of antithrombotic therapy in coronary artery disease  
Evaluation of out‑of‑hospital cardiac arrest patients in the catheterization laboratory  
Out‑of‑hospital cardiac arrest management guidelines  
Management of patients at risk for and with left ventricular thrombus (ACC/AHA)  
Non‑obstructive coronary artery disease (MINOCA)  
Sex‑specific criteria for myocardial infarction diagnosis  
Statin use disparities in post‑MI patients  
Guidelines for prevention of acute coronary syndrome.

Page 66 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Myocardial Infarction (MI)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndrome (NSTE‑ACS)  
- Coronary Artery Disease (CAD)  
- Chronic Coronary Disease  
- Chest Pain (diagnostic evaluation)  
- Prehospital 12‑lead Electrocardiography (ECG)  
- Cardiac Arrest (during transport or self‑transport)  
- Primary Percutaneous Coronary Intervention (PCI)  
- Fibrinolytic (Thrombolytic) Therapy  
- Mechanical Reperfusion  
- Spontaneous Coronary Artery Dissection (SCAD)  
- Type 2 Myocardial Infarction  
- Acute Non‑Ischemic Myocardial Injury  
- Cardiovascular Risk (post‑MI)  
- Left Bundle‑Branch Block (LBBB)  
- STEMI Equivalent (e.g., LBBB‑equivalent ECG)  
- Electrocardiogram (ECG) Interpretation  
- ST‑Segment Elevation (in ECG)  
- Door‑to‑Balloon Time  
- Emergency Medical Services (EMS) Transport  
- Prehospital Notification/Advance Notification  
- Regionalization of STEMI Care  
- Cath Lab Preactivation  
- Reperfusion Timing Metrics  
- Prehospital Serial ECGs  
- Chest Pain Evaluation Guidelines  
- STEMI Receiving Center (SRC) Networks  

These terms capture the core heart‑disease concepts addressed in the guideline excerpts.

Page 67 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Acute Chest Pain  
- Myocardial Infarction (MI)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Myocardial Infarction (NSTEMI)  
- High‑sensitivity Troponin (TnT / TnI)  
- Conventional Troponin  
- Electrocardiogram (ECG)  
- 0/1‑hour Algorithm (ESC)  
- 0/3‑hour Algorithm (ESC)  
- HEART Pathway  
- EDACS (Emergency Department Assessment of Chest Pain Score)  
- TIMI Risk Score  
- GRACE Risk Score  
- PURSUIT Risk Score  
- Coronary Artery Disease (CAD)  
- Angiographic Severity  
- Ejection Fraction  
- Heart Failure  
- Right Ventricular Infarction  
- Biomarkers of Cardiac Damage  
- Clinical Decision Rules  
- Rapid Rule‑Out Strategies  
- Risk Stratification Tools  
- Universal Definition of Myocardial Infarction (2018)  
- Coronary Risk Scores  
- Lung Ultrasound (in ACS)  
- Coronary Care Unit  
- Emergency Department (ED) Management of Chest Pain  
- Mortality Prediction  
- Clinical Outcomes in ACS  
- Standardization of Cardiac Biomarker Assays  
- Diagnostic Performance of Troponin Assays  
- Chest Pain Evaluation Guidelines (AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR)  
- Acute Coronary Syndrome Management Algorithms  
- Short‑term and Long‑term Outcomes in MI  
- Biomarker Utilization in ACS  
- Ischemic and Bleeding Risk Assessment  

These terms capture the primary concepts and tools related to heart disease discussed throughout the cited clinical statements and guidelines.

Page 68 Extracted Terms:
- Acute coronary syndrome  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation acute coronary syndrome (NSTE‑ACS)  
- Myocardial infarction  
- Cardiac arrest  
- Out‑of‑hospital cardiac arrest  
- Cardiogenic shock  
- Coronary angiography  
- Percutaneous coronary intervention (PCI)  
- Oxygen therapy  
- High‑sensitivity troponin  
- Troponin I  
- Troponin T  
- NT‑proBNP (N‑terminal pro‑B‑type natriuretic peptide)  
- SCAI stage classification  
- SCAI grade  
- MIRACLE score  
- PEARL study  
- COACT trial  
- EMERGE trial  
- ARREST trial  
- NULL‑PLEASE score  
- OHCA score (Out‑of‑Hospital Cardiac Arrest score)  
- CAHP score (Cardiac Arrest Hospital Prognosis)  
- Early invasive strategy  
- Early versus delayed coronary angiography  
- Targeted temperature management  
- Catheterization laboratory management of comatose patients  
- American Heart Association scientific statement  
- European Society of Cardiology (ESC) guideline  
- American Heart Association guideline on cardiogenic shock  
- ACC/AHA guideline on acute coronary syndromes  
- SCAI expert consensus statement on out‑of‑hospital cardiac arrest  
- SCAI expert consensus on shock stage classification  
- SCAI grade for cardiac arrest  
- PARADISE‑MI trial (NT‑proBNP prognostication)  
- MERLIN‑TIMI 36 trial (cardiac biomarker assessment)  
- VALIANT study (heart failure post‑MI predictors)  
- JACC review topic of the week (cardiac shock care centers)  
- SCAI SHOCK stage classification update  
- Early predictors of poor outcome after cardiac arrest (e.g., neurological recovery)  
- Oxygenation strategies in acute myocardial infarction  
- High‑flow oxygen in suspected acute coronary syndrome  
- Air versus oxygen therapy in STEMI  
- SOCCER trial (oxygen therapy on myocardial salvage)

Page 69 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation acute coronary syndrome (NSTE‑ACS)  
- Acute myocardial infarction (AMI)  
- Unstable angina  
- Coronary artery disease (CAD)  
- Ischemia  
- Oxygen therapy  
- Oxygen saturation  
- Nitroglycerin (nitroglycerin spray, sublingual tablets, intravenous)  
- Isosorbide dinitrate  
- Nitro‑vasodilators  
- Morphine  
- Fentanyl  
- Clopidogrel  
- Aspirin (acetylsalicylic acid)  
- Ticagrelor  
- Prasugrel  
- P2Y12 inhibitors  
- Intravenous streptokinase  
- Oral aspirin  
- Low‑dose aspirin  
- High‑dose aspirin  
- NSAIDs (non‑steroidal anti‑inflammatory drugs)  
- COX‑2 inhibitors  
- Cyclo‑oxygenase‑2 inhibitors  
- Aspirin sensitivity/desensitization  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Platelet inhibition  
- Primary percutaneous coronary intervention (PCI)  
- Coronary angiography  
- Coronary angioplasty  
- Restenosis  
- Beta‑blockers (implicit in ACS management)  
- Antihypertensive drugs (early treatment)  
- Heparin  
- Nitroglycerin‑sildenafil interaction (tadalafil, avanafil, sildenafil citrate)  
- Ventricular function  
- Mortality and morbidity in ACS  
- Meta‑analysis and systematic review (reference to methodology)  
- Clinical trials: GISSI‑3, ISIS‑4, ISIS‑2, Antithrombotic Trialists Collaboration, PLATO, Wiviott SD (prasugrel trial), Sabatine MS (clopidogrel addition), Yusuf S (clopidogrel + aspirin), Chen ZM (clopidogrel + aspirin), etc.  

Page 70 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation acute coronary syndrome (NSTE‑ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Saphenous vein graft  
- Platelet inhibition  
- Antiplatelet therapy  
- P2Y12 inhibitors  
- Ticagrelor  
- Clopidogrel  
- Prasugrel  
- Cangrelor  
- Glycoprotein IIb/IIIa inhibitors  
- Abciximab  
- Eptifibatide  
- Tirofiban  
- Bivalirudin  
- Heparin  
- Fibrinolytics  
- Aspirin  
- Intravenous (IV) platelet blockade  
- Intracoronary (IC) blockade  
- Intravenous cangrelor during PCI  
- Intravenous glycoprotein IIb/IIIa inhibitors  
- Clopidogrel response variability  
- Genetic determinants of clopidogrel response  
- CYP2C19 polymorphisms  
- Reperfusion therapy  
- Primary PCI  
- Pre‑PCI pretreatment  
- Pre‑hospital ticagrelor  
- Pre‑hospital abciximab  
- Aspiration thrombectomy  
- Transradial rescue PCI  
- PRISM‑PLUS trial  
- INFUSE‑AMI trial  
- MISTRAL study  
- 2025 Acute Coronary Syndromes Guideline  
- 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for Chronic Coronary Disease  
- Dual antiplatelet therapy (DAPT)  
- Combination of clopidogrel and aspirin  
- Recurrent ischemic events  
- Mortality benefit (in CABG context)  
- Coronary artery  
- Myocardial infarction  
- Unstable angina  
- Non‑Q‑wave myocardial infarction  
- Randomized double‑blind study  
- Prospective randomized study  
- Systematic review and meta‑analysis  
- Randomized clinical trial  
- Platelet reactivity  
- Antiplatelet response  
- Pre‑treated P2Y12 inhibitors  
- Intraprocedural outcomes  
- Cardiovascular events  
- Major bleeding  
- Intracoronary infusion of abciximab  
- Intravenous infusion of abciximab  
- Intravenous infusion of eptifibatide  
- Intravenous infusion of tirofiban  
- Intracoronary versus intravenous drug administration  

These terms capture the core concepts, interventions, medications, study designs, and guideline references related to heart disease present in the supplied text.

Page 71 Extracted Terms:
**Key Heart‑Disease Terms Identified**

- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Unstable angina (unstable coronary artery disease)  
- Myocardial infarction (MI)  
- Percutaneous coronary intervention (PCI)  
- Primary PCI  
- Revascularization  
- Coronary artery revascularization  
- Intracoronary drug delivery  
- Intravenous drug delivery  
- Anticoagulation  
- Antithrombotic therapy  
- Glycoprotein IIb/IIIa inhibitors  
- Bivalirudin  
- Enoxaparin (low‑molecular‑weight heparin)  
- Unfractionated heparin  
- Fondaparinux  
- Heparin‑induced thrombocytopenia (HIT)  
- Argatroban  
- Ticagrelor  
- Clopidogrel  
- Eptifibatide  
- Abciximab  
- Tenecteplase  
- Recombinant tissue plasminogen activator (rt‑PA) / tissue plasminogen activator (tPA)  
- Thrombolysis / thrombolytic therapy  
- Thrombin generation / activity  
- Activated clotting time (ACT)  
- Reperfusion therapy  
- Global Use of Strategies To Open Coronar‑y Arteries (GUSTO)  
- ACC/AHA/SCAI guideline  
- 4th Universal Definition of Myocardial Infarction  
- Coronary artery disease (CAD)  
- Coronary intervention (including transradial PCI)  
- Acute Catheterization and Urgent Intervention Triage (ACUITY) trial  
- OASIS, ATOLL, FUTURA/OASIS‑8, STENIC, BRIGHT, GUSTO‑IIb, etc. (key clinical trials/registries)  
- Aspirin therapy  
- Parenteral anticoagulation strategies  
- Coronary artery stenosis  
- Coronary artery thrombosis  

These terms capture the major clinical entities, interventions, medications, and guideline references relevant to heart disease as presented in the supplied text.

Page 72 Extracted Terms:
- Acute Coronary Syndromes  
- ST‑elevation myocardial infarction  
- Myocardial infarction  
- Coronary artery disease  
- Chest pain / angina  
- Heart failure  
- Arrhythmia  
- Atherosclerosis  
- Ischemia  
- Revascularization  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Cardiovascular disease (CVD)  
- Cardiovascular events  
- Statin therapy  
- Atorvastatin  
- Simvastatin  
- Rosuvastatin  
- Pravastatin  
- Ezetimibe  
- PCSK9 inhibitors  
- Evolocumab  
- Alirocumab  
- Bempedoic acid  
- Inclisiran  
- Lipid management  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Very‑low LDL‑C  
- High‑density lipoprotein cholesterol (HDL‑C)  
- Total cholesterol  
- Triglycerides  
- Lipoprotein(a)  
- Lipid‑lowering therapy  
- Statin intolerance  
- Cardiovascular risk stratification  
- High‑risk cardiovascular profile  
- Biomarkers (troponin, high‑sensitivity troponin)  
- Clinical trials / studies  
- MIRACL trial  
- A to Z trial  
- IMPROVE‑IT trial  
- FOURIER trial  
- ODYSSEY OUTCOMES trial  
- EVOPACS trial  
- PROVE‑IT‑TIMI 22 study  
- CLEAR Wisdom trial  
- GAUSS‑3 trial  
- PIONEER trials (not explicitly mentioned but implied by PCSK9 inhibitors)  
- Guidelines (AHA/ACC, ACC/AHA/ACC/AAPA, etc.)  
- Guidelines for cholesterol management  
- Guidelines for acute coronary syndromes  
- Guidelines for statin intolerance  
- Guidelines for high‑risk cardiovascular disease  
- Peripheral artery disease (as a manifestation of CVD)  
- Polyvascular disease  
- Atherogenic lipoproteins  
- Coronary plaque assessment  
- Coronary plaque phenotype  
- Coronary plaque burden  
- Cardiovascular outcomes  
- Mortality post‑myocardial infarction  
- Recurrent cardiovascular events  
- Risk reduction strategies  
- Lipid‐lowering intensity  
- LDL‑C level targets  
- Lipid‑lowering agents  

(Any term related to a heart‑related condition, its treatment, risk assessment, or evidence source has been included.)

Page 73 Extracted Terms:
Acute Coronary Syndromes  
Acute myocardial infarction  
ST‑segment elevation myocardial infarction (STEMI)  
Beta‑blocker therapy  
Metoprolol  
Carvedilol  
Captopril  
Ramipril  
Valsartan  
Telmisartan  
Enalapril  
Eplerenone  
Angiotensin‑converting‑enzyme inhibitor (ACE‑I)  
Angiotensin receptor blocker (ARB)  
Angiotensin‑neprilysin inhibitor (ARNI)  
Neprilysin inhibition  
Aldosterone blocker  
Percutaneous coronary intervention (PCI)  
Primary PCI (PPCI)  
Door‑to‑balloon time  
Thrombolytic therapy  
Primary angioplasty  
Revascularization  
Cardiogenic shock  
Heart failure  
Left ventricular dysfunction  
Left ventricular ejection fraction  
Infarct size  
Mortality  
Morbidity  
Vascular events  
Regional STEMI system  
STEMI network  
FAST‑MI program  
FITT‑STEMI trial  
Mission: Lifeline STEMI system  
Cardioprotection

Page 74 Extracted Terms:
- Acute coronary syndrome  
- Acute myocardial infarction  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Coronary artery bypass graft (CABG)  
- Percutaneous coronary intervention (PCI)  
- Primary percutaneous coronary intervention (PPCI)  
- Angioplasty  
- Reperfusion therapy  
- Mechanical reperfusion  
- Thrombolytic therapy  
- Fibrinolysis  
- Coronary artery revascularization  
- Cardiogenic shock  
- Door‑to‑balloon time  
- Emergency medical services (EMS)  
- Regionalization of STEMI care  
- Transradial access  
- Transfemoral access  
- Coronary artery disease  
- Infarct‑related artery  
- STEMI networks  
- Pharmacoinvasive strategy  
- Primary PCI versus thrombolysis  
- Recurrent myocardial infarction  
- Coronary intervention strategy  
- Revascularization strategy  
- Clinical outcomes after myocardial infarction  
- Time to reperfusion  
- Late presentation of myocardial infarction  
- Transfer for PPCI (interhospital transfer)

Page 75 Extracted Terms:
- Acute myocardial infarction  
- ST‑segment‑elevation myocardial infarction (STEMI)  
- Non‑ST‑segment‑elevation myocardial infarction (NSTEMI)  
- Acute coronary syndrome (ACS)  
- Percutaneous coronary intervention (PCI)  
- Primary PCI  
- Rescue angioplasty / rescue PCI  
- Coronary angiography  
- Coronary artery revascularization  
- Pharmacoinvasive strategy  
- Fibrinolytic therapy  
- Thrombolytic therapy (intravenous thrombolysis)  
- Tissue plasminogen activator (t‑PA)  
- Alteplase (Alteplase)  
- Front‑loaded alteplase administration  
- Tenecteplase (TNK‑tPA)  
- Reteplase  
- ST‑segment resolution / ST‑resolution  
- Door‑in–door‑out time  
- Reperfusion therapy  
- Meta‑analysis of reperfusion strategies  
- Transradial or radial artery access for coronary intervention  
- ACC/AHA/SCAI guideline for coronary artery revascularization  
- ACC/AHA guideline for acute coronary syndromes  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- TIMI trial (Thrombolysis In Myocardial Infarction)  
- NORDISTEMI study  
- STREAM trial  
- MERLIN trial  
- GRAcia‑1 trial  
- Capital AMI study  
- Late Assessment of Thrombolytic Efficacy (LATE) study  
- Early invasive strategy  
- Standard therapy versus early routine PCI after fibrinolysis  

*(All terms are extracted directly from the references and guideline citations, focusing on cardiovascular conditions, interventions, and key clinical concepts mentioned in the text.)*

Page 76 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Acute coronary syndrome (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation myocardial infarction (NSTEMI)  
- Unstable angina  
- Myocardial infarction (MI)  
- Coronary artery disease (CAD)  
- Coronary angiography  
- Percutaneous coronary intervention (PCI)  
- Coronary artery revascularization  
- Coronary artery bypass grafting (CABG)  
- Radial access (radial artery approach)  
- Femoral access (femoral artery approach)  
- Trans‑ulnar access  
- Trans‑radial access (conventional & distal)  
- Aspiration thrombectomy (thrombus aspiration)  
- Thrombectomy (manual, intracoronary)  
- Glycoprotein IIb/IIIa inhibitor (e.g., tirofiban)  
- Intracoronary abciximab  
- Radial artery graft vs. saphenous vein graft  
- Routine invasive strategy  
- Selective invasive strategy  
- Early invasive strategy  
- Delayed invasive strategy  
- Timing of intervention  
- Meta‑analysis (individual‑patient data, randomized trial)  
- Randomized controlled trial (RCT)  
- Multicentre study  
- Clinical guideline / statement  
- ACC/AHA/SCAI guideline  
- ACC/AHA guideline  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- National cardiovascular data registries  
- Cardiovascular outcomes  
- Mortality (all‑cause, cardiovascular)  
- Major bleeding  
- Safety and efficacy  
- Patient preference (vascular access)  
- Prospective randomised trial  
- Early invasive vs. conservative strategy  
- Long‑term outcome  
- Individual‑patient data meta‑analysis.

Page 77 Extracted Terms:
- Acute Coronary Syndromes  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑segment Elevation Myocardial Infarction (NSTEMI)  
- Acute Myocardial Infarction  
- Myocardial Infarction  
- Coronary Artery Disease (CAD)  
- Coronary Revascularization  
- Primary Percutaneous Coronary Intervention (PCI)  
- Angioplasty  
- Coronary Angiography  
- Drug‑Eluting Stent (DES)  
- Bare‑Metal Stent (BMS)  
- Stent Thrombosis  
- Thrombus Aspiration  
- Intravascular Ultrasound (IVUS)  
- Optical Coherence Tomography (OCT)  
- Optical Frequency Domain Imaging (OFDI)  
- Intravascular Imaging  
- Intravascular Imaging‑Guided PCI  
- Angiography‑Guided PCI  
- Fractional Flow Reserve (FFR)  
- Multivessel Coronary Disease  
- Complete Revascularization  
- Culprit Lesion  
- Staged Revascularization  
- Preventive Angioplasty  
- Cardiogenic Shock  
- Reperfusion  
- Distal Embolization  
- Infarct Size  
- Infarct‑Related Artery  
- Revascularization Strategy  
- PCI Strategies  
- Acute Coronary Intervention  
- Coronary Stent Implantation  
- Coronary Intervention  
- Imaging Guidance in PCI  
- Stent Implantation   
- Coronary Angiographic Guidance  



Page 78 Extracted Terms:
- Acute coronary syndrome (ACS)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Myocardial infarction (MI)  
- Coronary artery disease (CAD)  
- Multivessel coronary artery disease  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)  
- Culprit‑only PCI  
- Complete revascularization  
- Staged revascularization  
- Immediate revascularization  
- Fractional flow reserve (FFR)  
- Angiography‑guided strategy  
- Drug‑eluting stents (DES)  
- Coronary artery bypass graft surgery  
- Cardiogenic shock  
- Ischemic cardiomyopathy  
- Left‑main coronary artery disease  
- Coronary artery revascularization  
- FAME study (Fractional flow reserve vs Angiography for Multivessel Evaluation)  
- FAMOUS‑NSTEMI trial  
- BIOVASC trial  
- SMILE trial  
- PRIME‑FFR study  
- POST‑IT registry  
- R3F registry  
- SYNTAX trial  
- ACC/AHA/SCAI revascularization guidelines  
- National Cardiovascular Data Registry (NCDR) ACTION registry  
- Timing of CABG after myocardial infarction  
- Coronary angiogram  
- Coronary arterial revascularization strategies  
- Hybrid revascularization strategies  
- Coronary artery bypass surgery outcomes  
- Cardiac catheterization laboratory use in ACS  
- Coronary arterial lesion assessment  
- Coronary arterial intervention outcomes  
- Coronary artery disease management guidelines  
- Revascularization decision‑making with FFR  
- Multivessel PCI vs culprit‑only PCI comparison  
- Early versus staged PCI in cardiogenic shock  
- Coronary artery disease in patients with diabetes  
- Left‑main coronary artery revascularization outcomes  
- Coronary artery bypass grafting mortality in cardiogenic shock  
- Coronary artery revascularization in ischemic cardiomyopathy  
- Coronary artery intervention trials and meta‑analyses  

(These terms capture the core concepts related to heart disease and coronary revascularization discussed in the provided guideline text.)

Page 79 Extracted Terms:
- Acute coronary syndrome  
- Cardiogenic shock  
- Myocardial infarction  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation myocardial infarction (NSTEMI)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Revascularization  
- Early revascularization  
- Mechanical circulatory support (MCS)  
- Extracorporeal membrane oxygenation (ECMO)  
- Venoarterial extracorporeal membrane oxygenation (VA‑ECMO)  
- Intra‑aortic balloon pump (IABP)  
- Intra‑aortic balloon counterpulsation (IABC)  
- Left ventricular assist device (LVAD)  
- Microaxial LVAD (Impella LP5.0)  
- Percutaneous LVAD (pLVAD)  
- Impella device  
- Mechanical complications of myocardial infarction  
- Post‑infarction mechanical complications  
- Ventricular septal rupture (VSR)  
- Ventricular free‑wall rupture  
- Papillary muscle rupture  
- Mitral valve surgery  
- Vascular access (femoral artery)  
- Ultrasound‑guided vascular access  
- Ultrasound‑guided femoral artery cannulation  
- FAUST trial (Femoral Arterial Access With Ultrasound Trial)  
- UNIVERSAL trial (routine ultrasound‑guided femoral vascular access)  
- IABP‑SHOCK II study  
- ECMO‑CS randomized clinical trial  
- IMPLESS‑STIC study (Impella plus IABP for cardiogenic shock)  
- SHOCK trial (cardiogenic shock after MI)  
- APEX‑AMI trial (mechanical complications after percutaneous coronary intervention)  
- GUSTO‑I trial (global utilization of streptokinase and tPA)  
- Nationwide registry data (e.g., Dutch, Japanese, UK national registries)  
- Society of Thoracic Surgeons (STS) database  
- Surgical repair of ventricular septal defect  
- Interventional closure of ventricular septal defect  
- Delayed surgery for VSR with mechanical circulatory support  
- Transition to heart transplantation after VSR  
- Risk factors for mechanical complications post‑MI  
- Angiographic patterns in VSR  
- Clinical outcomes (short‑term, long‑term survival)  
- Mortality prediction in cardiogenic shock  
- Major bleeding risk with MCS devices  
- Cost‑effectiveness of MCS strategies  
- Randomized controlled trial (RCT)  
- Meta‑analysis of MCS devices  
- Retrospective cohort study  
- Temporal trends in cardiogenic shock incidence  
- Cardiogenic shock classification systems  
- Cardiac intensive care unit (CICU) outcomes  
- Mechanical bridge to definitive treatment  
- Early surgical intervention post‑MI  
- Vascular complications from device insertion  
- Patient‑characteristics influencing MCS outcomes

Page 80 Extracted Terms:
- Acute Coronary Syndromes  
- Coronary Artery Disease  
- Acute Myocardial Infarction  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Segment Elevation Myocardial Infarction (NSTEMI)  
- Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention  
- Coronary Revascularization  
- Coronary Artery Bypass Graft (CABG)  
- Cardiogenic Shock  
- Cardiac Free‑Wall Rupture  
- Cardiac Tamponade  
- Mechanical Complications of Myocardial Infarction  
- Acute Mitral Regurgitation  
- Papillary Muscle Tear  
- Transcatheter Edge‑to‑Edge Mitral Valve Repair  
- Ventricular Septal Defect  
- Intra‑aortic Balloon Pump/Support  
- Left Ventricular Dysfunction  
- Reduced Ejection Fraction  
- Heart Failure  
- Sudden Cardiac Death  
- Ventricular Arrhythmias  
- High‑Degree Atrioventricular (AV) Block  
- First‑Degree AV Block  
- Second‑Degree AV Block (Mobitz I & II)  
- Third‑Degree (Complete) AV Block  
- Bradycardia  
- Conduction Delay  
- Electro‑Mechanical Dissociation  
- Temporary Pacemaker  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Wearable Cardioverter‑Defibrillator  
- Catheter Ablation of Ventricular Fibrillation  
- Electrophysiologic Testing  
- Electrophysiology  
- Atrial Fibrillation  
- Pericarditis  
- Post‑Pericardiotomy Syndrome  
- Pericardial Effusion  
- Recurrent Pericarditis  
- Colchicine Therapy  
- Aspirin Therapy for Pericarditis  
- Indomethacin Therapy for Pericarditis  
- Prednisone Therapy for Pericarditis  
- Clinical Arrhythmias  
- Secondary Prevention of Arrhythmias  
- Primary Prevention of Arrhythmias  
- Risk Stratification after Myocardial Infarction  
- Cardiac Conduction System  
- Acute Coronary Event Complications  
- Post‑Revascularization Arrhythmic Risk  
- Implantation Timing of ICD  
- ICD Therapy Compliance  
- Cardiac Electrophysiology Procedures  
- Acute Coronary Syndrome Management  
- Post‑MI Management  
- Acute Coronary Syndromes Guideline  
- Cardiogenic Shock Guideline  
- Heart Rhythm Society Guidelines.

Page 81 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Acute Myocardial Infarction (AMI)  
- ST‑segment‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑segment‑Elevation Myocardial Infarction (NSTEMI)  
- Left Ventricular Thrombus  
- Left Ventricular Thrombosis  
- Peripheral Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention (Primary PCI)  
- Coronary Angioplasty  
- Cardiac Magnetic Resonance Imaging (CMR)  
- Post‑operative Pericardial Effusion  
- Pericarditis (acute)  
- Colchicine Therapy for Pericarditis  
- Non‑steroidal Anti‑inflammatory Drugs (NSAIDs) for Pericardial Effusion  
- Steroid Therapy during Myocardial Infarction  
- Left Ventricular Free‑Wall Rupture  
- Arrhythmias  
- Sustained Ventricular Tachycardia (VT)  
- Ventricular Fibrillation (VF)  
- Telemetry Monitoring  
- Cardiac Intensive Care Unit (CICU)  
- Anemia in Acute Coronary Syndromes  
- Red Blood Cell Transfusion  
- Transfusion Thresholds (Restrictive vs. Liberal)  
- Blood Transfusion Guidelines (AABB, Cochrane Review)  
- Major Cardiovascular Events  
- Major Bleeding  
- Mortality (in-hospital and long‑term)  
- Prognostic Assessment after Primary Angioplasty  
- Early Discharge After PCI/Angioplasty  
- Length of Hospital Stay  
- Post‑acute Care Planning  
- Risk Scores (e.g., for need of intensive care, predicting length of stay)  
- Telemetry‑based Prediction of In‑hospital Adverse Outcomes  
- STEMI Surveillance (e.g., ischemic ST‑segment episodes)  
- Acute Catheterization and Urgent Intervention Trials (ACUIT)  
- Real‑world Outcomes after Transfusion Strategies (REALITY trial)  

*(This list captures the principal disease‑related concepts, clinical entities, diagnostic modalities, therapeutic interventions, and outcome measures present in the cited guideline excerpt.)*

Page 82 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI)  
- Acute Myocardial Infarction (AMI)  
- Coronary Heart Disease (CHD)  
- Coronary Artery Disease (CAD)  
- Heart Failure (HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- Left Ventricular Function  
- Cardiac Magnetic Resonance Imaging (MRI)  
- Percutaneous Coronary Intervention (PCI)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Noninvasive Diagnostic Testing  
- Cardiac Rehabilitation (CR)  
- Home‑based Cardiac Rehabilitation  
- Telehealth Cardiac Rehabilitation  
- Secondary Prevention of MI  
- Medication Adherence / Medication‑Taking  
- Readmission / Rehospitalization after ACS  
- Hospital‑to‑Home Initiatives  
- Life’s Essential 8 (AHA)  
- Acute Coronary Syndrome Toolkit (AHA)  
- Clinical Outcomes (mortality, morbidity, quality of life)  
- Cardiovascular Risk Factors (hypertension, diabetes, dyslipidemia)  
- Mechanical Complications of MI  
- Left Ventricular Thrombus  
- Chronic Coronary Disease (CCSD)  
- Multimorbidity in ACS patients  
- Clinical Practice Guidelines (ACC/AHA, AHA/ACC/JACC)  
- American Heart Association (AHA) Statements/Guidelines  
- American College of Cardiology (ACC) Guidelines  
- Chronic Coronary Disease Management  
- Readiness and Utilization of Cardiac Rehabilitation  
- Cardiovascular Magnetic Resonance (CMR) Studies  
- Stress Testing (noninvasive)  
- Patient Education strategies in ACS  
- Socioeconomic status and cardiovascular outcomes  
- Telehealth and remote rehabilitation efficacy 

Page 83 Extracted Terms:
- Acute Coronary Syndromes  
- Cardiac Rehabilitation  
- Intensive Cardiac Rehabilitation  
- Exercise Training  
- Physical Activity  
- Coronary Artery Bypass Grafting (CABG)  
- Percutaneous Coronary Intervention (PCI)  
- Stenting  
- Dual Antiplatelet Therapy (DAPT)  
- Ticagrelor  
- Clopidogrel  
- Aspirin  
- P2Y12 Inhibitors  
- Platelet Inhibition  
- Drug‑Eluting Stents  
- Myocardial Infarction  
- Unstable Angina  
- ST‑Elevation MI  
- Non‑ST‑Elevation MI  
- Coronary Thrombosis  
- Bleeding Risk  
- Major Bleeding  
- High Bleeding Risk  
- Proton Pump Inhibitor (PPI)  
- Omeprazole  
- Lansoprazole  
- Pantoprazole  
- Gastrointestinal Bleeding  
- Secondary Coronary Prevention  
- Coronary Risk Factors  
- Cardiovascular Outcomes  
- Mortality  
- Cardiovascular Events  
- Risk Scoring (e.g., PRECISE‑DAPT, PARIS)

Page 84 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI)  
- Unstable Angina  
- Coronary Artery Disease (CAD)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Stenting (Drug‑Eluting Stent, Bare‑Metal Stent)  
- Coronary Artery Revascularization  
- Atrial Fibrillation (AF)  
- Chronic Coronary Disease  
- Coronary Stent Implantation  
- Stent‑Induced Intimal Hyperplasia  
- Dual Antiplatelet Therapy (DAPT)  
- Dual Antithrombotic Therapy (DAT)  
- Triple Therapy  
- P2Y12 Inhibitor  
- Clopidogrel  
- Ticagrelor  
- Prasugrel  
- Aspirin  
- Platelet Inhibition  
- Platelet Function Testing  
- Platelet Reactivity  
- Clopidogrel Resistance  
- Antiplatelet Therapy  
- Antithrombotic Therapy  
- Dabigatran  
- Edoxaban  
- Warfarin  
- Vitamin K Antagonist  
- Non‑Vitamin K Antagonist Oral Anticoagulants (NOACs)  
- Prolonged Dual Antiplatelet Therapy  
- Short‑Term Dual Antiplatelet Therapy  
- Duration of Dual Antiplatelet Therapy (3 , 6 , 12 , 24 months)  
- Proton Pump Inhibitor (PPI)  
- Cytochrome P450 Polymorphisms  
- Clinical Outcomes  
- Major Adverse Cardiac Events (MACE)  
- Bleeding Risk  
- High Bleeding Risk  
- Coronary Artery Disease with Atrial Fibrillation

Page 85 Extracted Terms:
- Acute Coronary Syndrome  
- Percutaneous Coronary Intervention (PCI)  
- Stent Thrombosis  
- Atrial Fibrillation  
- Antithrombotic Therapy  
- Aspirin  
- Dual Antiplatelet Therapy (DAPT)  
- Triple Antithrombotic Therapy  
- High Bleeding Risk  
- Oral Anticoagulation  
- Statin Therapy  
- Low‑Density Lipoprotein (LDL) Cholesterol  
- Intensive Lipid Lowering  
- Lipid‑Lowering Therapy  
- Cholesterol Management  
- Atherosclerotic Cardiovascular Disease  
- Myocardial Infarction  
- Heart Failure  
- Reduced Ejection Fraction (HFrEF)  
- Preserved Ejection Fraction (HFpEF)  
- Mildly Reduced Ejection Fraction  
- SGLT‑2 Inhibitors (e.g., dapagliflozin, empagliflozin, canagliflozin)  
- GLP‑1 Receptor Agonists (e.g., semaglutide, liraglutide)  
- Chronic Colchicine (low‑dose colchicine)  
- Anti‑Inflammatory Therapy  
- Platelet‑Leukocyte Interaction  
- Perioperative Cardiovascular Management  
- Preoperative Fasting in Cardiac Patients  




Page 86 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Acute Coronary Syndrome (ACS)  
- Myocardial infarction (MI)  
- Coronary artery disease (CAD)  
- Coronary heart disease (CHD)  
- Cardiovascular events  
- Cardiovascular death  
- Cardiovascular mortality  
- Cardiovascular outcomes  
- Plaque stabilization  
- Chronic coronary disease  
- Secondary prevention of coronary ischemic events  
- Cardiovascular disease (CVD)  

These terms capture the primary concepts related to heart disease discussed in the provided excerpt.

Page 87 Extracted Terms:
- Acute Coronary Syndromes  
- Interventional Cardiology  
- Cardiovascular Medicine  
- Cardiac Surgery  
- Heart Failure  
- Acute MI (myocardial infarction)  
- PCI (percutaneous coronary intervention)  
- Structural Heart Interventions  
- Coronary  
- Heart & Vascular Center  
- TIMI Study Group  
- Heart Disease  
- Cardiology  
- Heart  
- MI  
- Injury after PCI  

Page 88 Extracted Terms:
- Acute Coronary Syndromes  
- Cardiology  
- Cardiac  
- Coronary  
- Heart  
- Heart disease  
- Heart center  
- Duke Heart Center  
- Heart and Vascular Center (Emory)  
- Emory Heart and Vascular Center  
- Center for Heart Disease Prevention  
- Cardiovascular  
- Cardiovascular disease  
- NHLBI (National Heart, Lung, and Blood Institute)  
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- Medtronic  
- Abbott  
- Roche Diagnostics  
- GlaxoSmithKline  
- Amgen  
- AstraZeneca  
- Beckman Coulter  
- Eli Lilly  
- Janssen Pharmaceuticals  
- Merck  
- Novo Nordisk  
- Regeneron  
- Siemens  
- Varian Medical Systems  
- Verve Therapeutics  
- LianBio  
- Cytokinetics  
- Novartis  
- Bodyport  

Page 89 Extracted Terms:
Acute Coronary Syndromes  
Cardiac ICU  
Cardiovascular Fellowship  
Cardiovascular Medicine  
Cardiovascular Division  
Cardiac Surgery  
Interventional Cardiology  
Heart Failure  
Cardiology  
Cardiovascular  
Cardiac  
American Heart Association (AHA)  
American College of Cardiology (ACC)  
Society for Cardiovascular Angiography and Interventions (SCAI)  
European Heart Journal–Acute Cardiovascular Care  
European Journal of Heart Failure  
Cardiovascular Care  
Cardiovascular Disease 

Page 90 Extracted Terms:
Acute Coronary Syndromes  
Coronary Artery Disease  
Interventional Cardiologist  
Cardiovascular Interventions  
Cardiac Rehabilitation  
Acute Cardiac Care  
Cardiac Bio‑Markers  
Pulmonary Embolism (cardiovascular event)  
Minneapolis Heart Institute  
Cleveland Clinic – Cardiac Care  
Heart Disease (general term)

Page 91 Extracted Terms:
- Acute Coronary Syndromes  
- Myocardial Infarction (MI)  
- Percutaneous Coronary Intervention (PCI)  
- Cardiovascular  
- Cardiovascular disease  
- Cardiology  
- Cardiac  
- Heart  
- Coronary artery disease  
- Coronary artery  
- Coronary  
- CardioVascular  
- TIMI (Thrombolysis in Myocardial Infarction)

Page 92 Extracted Terms:
- Acute Coronary Syndromes  
- Acute Coronary Syndrome guideline  
- Coronary artery disease  
- Coronary artery  
- Right coronary artery  
- Angioplasty  
- Stent placement  
- Perforation during angioplasty  
- Spontaneous bleed  
- Iatrogenic dissection of right coronary artery  
- Cardiac catheterization laboratory  
- Cardiac catheterization  
- Interventional cardiology  
- Cardiovascular medicine  
- Cardiac electrophysiology  
- Cardiovascular service line  
- Heart rhythm (as in Heart Rhythm Society)  
- Coronary revascularization  
- Cardiovascular intervention  
- Acute myocardial infarction (implied within ACS context)  
- Cardiac catheterization laboratory procedure  
- Coronary artery intervention  
- Stenting  
- Coronary artery bypass (implied by angioplasty context)  
- Cardiovascular risk management  
- Cardiac catheterization procedure  
- Coronary artery disease management  
- Cardiac electrophysiology procedure  
- Coronary artery intervention outcomes  
- Cardiovascular disease (general)

